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Abstract
FRANK OCTAVE BARTEL, III. Generation and Characterization of an Allelic
Series of Ets1 Gene Targeted Mice: Thymomegaly, Microsplenia and Defective
Homeostatic Proliferation of Peripheral Lymphocytes of Ets1j).VII but not Ets1 s->A
Mice (Under the direction of DEMETRI SPYROPOULOS).

Ets1 is a member of the ETS transcription factor family with demonstrated
roles in cell proliferation, migration, and survival. Alternative splicing of exon
VII results in two distinct protein isoforms: full length Ets1 and Ets1j).VII.
These isoforms bear key distinctions regarding protein-protein interactions,
DNA binding kinetics and transcriptional target specificity. Targeted
disruption of both Ets1 isoforms (Ets1 nUll) in mice results in increased
perinatal lethality, loss of detectable NK and NKT cell activity, and
differentiation, proliferation and survival defects in B- and T-Iymphocytes. To
further delineate the individual roles of Ets1 isoforms in vivo we have
generated an allelic series of Ets1 gene targeted mice. One line expresses
only the Ets1 j).VII isoform. These Ets1 j). VII mice present with increased
perinatal lethality, thymomegaly, as well as variable splenic and peripheral
lymphopenia. Rates of apoptosis were diminished in the thymus and
increased in the spleen of homozygotes. Increased rates of cell proliferation
were also observed in both spleen and thymus with concomitant reduction in
expression of both Cdkn1 band Cdkn2a proteins. Statistically significant
elevation in CD4-CDS+ and CDS+CD4+ thymocyte calculated cell mass was

IX

observed in homozygote thymuses. Diminished cellularity in the spleen was
due to reductions in the numbers of lymphoid cells (CD19+, CD4+, and CD8+).
Two putative Ets1 target genes important in thymopoiesis, CD44 and RUNX1
were found to be misexpressed in the thymuses of homozygous mutant mice.
Collectively these results demonstrate that Ets1 ~VII results in apoptotic and
differentiative defects in lymphocytes and these defects are associated with
misregulation of the putative target genes CD44 and RUNX1. Another line of
mice in this allelic series, Ets1 S->A, contains serine to alanine conversions in a
critical domain coded by exon VII. This mutation abrogates phosphorylation
mediated inhibition of Ets1 DNA binding. These mice present with a minimal
phenotype suggestive that this autoinhibitory process is not central to the
phenotypes observed in Ets1 ~VII mice. Targeted ES cells have been
generated for a third line of mice expressing only full-length Ets1. Our results
have demonstrated that regulation of Ets1 isoforms represents a mechanism
in the maintenance of normal lymphoid homeostasis.
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IF

If you can keep your head when all about you
Are losing theirs and blaming it on you,
If you can trust yourself when all men doubt you
But make allowance for their doubting too,
If you can wait and not be tired by waiting,
Or being lied about, don't deal in lies,
Or being hated, don't give way to hating,
And yet don't look too good, nor talk too wise:
If you can dream--and not make dreams your master,
If you can think--and not make thoughts your aim;
If you can meet with Triumph and Disaster
And treat those two impostors just the same;
If you can bear to hear the truth you've spoken
Twisted by knaves to make a trap for fools,
Or watch the things you gave your life to, broken,
And stoop and build 'em up with worn-out tools:
If you can make one heap of all your winnings
And risk it all on one turn of pitch-and-toss,
And lose, and start again at your beginnings
And never breath a word about your loss;
If you can force your heart and nerve and sinew
To serve your turn long after they are gone,
And so hold on when there is nothing in you
Except the Will which says to them: "Hold on!"
If you can talk with crowds and keep your virtue,
Or walk with kings--nor lose the common touch,
If neither foes nor loving friends can hurt you;
If all men count with you, but none too much,
If you can fill the unforgiving minute
With sixty seconds' worth of distance run,
Yours is the Earth and everything that's in it,
And--which is more--you'li be a Man, my son!

--Rudyard Kipling
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Chapter 1: Background and Review of the Literature

1.1 The Ets Family of Transcription Factors

1.1.1 Discovery and Definition
The Ets family of transcription factors is among the largest groups of
transcription factors conserved throughout metazoa (Degnan, Degnan et al.
1993; Tupler, Perini et al. 2001). The first Ets gene, Ets1, was discovered
based upon sequence similarity to the gag-myb-ets fusion protein of the avian
erythroblastosis retrovirus E26, for which the family is named (E26
!ransformation-!pecific) (Nunn, Seeburg et al. 1983; Watson, McWiliiamsSmith et al. 1985; Ghysdael, Gegonne et al. 1986). The family is comprised
of at least 27 transcription factors in humans (Maglott, Ostell et al. 2005). Of
these, 26 are known to have murine orthologs; ETV7 being the singular
exception (Fig 1.1) (Maglott, Ostell et al. 2005). The family is defined by the
presence of an approximately 86 amino acid DNA binding domain which
recognizes the core DNA consensus binding sequence 5'-GGAW-3' in the
major groove of DNA (Nye, Petersen et al. 1992; Graves and Petersen 1998).
The structural characterization of the Ets1 :DNA binding interface has been
well studied, and demonstrated by x-ray crystallography at 2.4A resolution
(Fig 1.2) (Werner, Clore et al. 1997; Obika, Reddy et al. 2003). Such studies,
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FIGURE 1.1 Murine Ets Family of Transcription Factors. The 26 known murine Ets factors aligned by their Ets DNA binding
domain. Colored boxes indicate putative conserved domains suggested by the motif discovery tool 'Multiple ~m for Motif
glucidation' (MEME). Black rectangular box highlights aligned ETS domain. Colored lines to the far left and left of sequence
names indicate Ets subfamilies and groups within each subfamily respectively as suggested by distance analysis a bootsrap
analysis of the Ets domain. Bottom figure shows an expanded view of the Ets1 DNA binding domain sequence with MEME
motifs indicated by color. a-helicies H1-H3, and b strands S1-S4 are indicated by underlined sequence. Residues directly
contacting phosphate backbone of DNA (*) or base pairs (x) are indicated above the sequence.

(a)

(b)

Figure 1.2. Crystal structure of Ets1 ETS domain-DNA
complex (PDB code: 1K79): (a) the whole structure, (b) the
close-up view of the ETS domain-DNA nucleobase contact
site (helix-3 and GGAA core sequence). Adopted from
OKIBA2003
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along with previous NMR studies (Donaldson, Petersen et al. 1996;
Kodandapani, Pio et al. 1996) have demonstrated that the Ets DNA binding
domain is a winged helix-tum-helix (wHTH) motif comprised of three a-helixes
(a1-a3) and four-stranded p-sheets (P1-P4) ordered

a1-~1-~2-a2-a3-~4,

with

a3 directly interacting with the base residues of the core Ets binding site. In
addition to the Ets domain, all Ets proteins have either a transactivation or
transrepression domain. Some Ets factors such as Elk1, Elk3, and Nerf have
the ability to act as both activators and repressors of transcription, while
others have been documented to act exclusively as repressors (e.g. TEL,
ERF) or activators (e.g. Ets2, ME F) (Sharrocks 2001). Paralogous Ets genes
exhibit structural and functional diversity, with the family commonly divided
into 4 sub-families (Ets, Elf, Tel, and Spi) collectively containing 11 subgroups
based upon sequence homology in the Ets domain (Graves and Petersen
1998). Eleven Ets factors in humans (10 in mice) also contain conserved
sequence coding for a protein-protein interaction domain, the pOinted domain
(Pnt). The pointed domain is named for sequence homology to the SAM
domain of Drosophila pointed protein, and has been shown to mediate
homotypic and heterotypic protein-protein interactions as well as
transcriptional repression (Lacronique, Boureux et al. 1997; Fenrick, Amann
et al. 1999; Baker, Mille-Baker et al. 2001; Kim, Phillips et al. 2001; Sharrocks
2001 ).

5

1.1.2 Function
Ets family members are important regulators of a broad range of cellular
functions including cell division, survival, differentiation, motility, and
senescence as well as pathologies related to these processes. In the control
of proliferation Ets factors are involved in the expression of receptors
signaling cell division (Hohaus, Petrovick et al. 1995; Fears, Gavin et al.
1997; Choi, Yi et al. 1998), the ligands of such receptors (Maul, Zhang et al.
1998; Chotani, Touhalisky et al. 2000; Coles, Diamond et al. 2000), signal
transduction cascades which transduce mitogenic signals (Gutman and
Wasylyk 1991; Wasylyk, Hagman et al. 1998; Krehan, Schmalzbauer et al.
2001; Oikawa and Yamada 2003), as well as direct regulation of cell cycle
control proteins (Albanese, Johnson et al. 1995; Tommasi and pfeifer 1995;
Tamir, Howard et al. 1999; Park, Qiao et al. 2000).

1.1.2.1 Cell Survival
Ets family members control cell survival by regulating the transcription of both
pro-apoptotic (Li, Pei et al. 1999; Li, Chong et al. 1999; Seth, Giunta et al.
1999; Soldatenkov, Albor et al. 1999; Liu, Wang et al. 2002) and antiapoptotic (Frampton, Ramqvist et al. 1996; Sevilla, Aperlo et al. 1999;
Townsend, Zhou et al. 1999; Hu, Rao et al. 2001; Irvin, Wood et al. 2003)
target genes. Further evidence for the central role of Ets factors in the
regulation of cell survival and apoptosis is provided by studies where Ets
factors are misexpressed, such as in transgenic overexpressor or knockout

6

models. For instance over-expression of Ets1 or Ets2 has been shown to
induce apoptosis in some cell types (Foos and Hauser 2000; Teruyama, Abe
et al. 2001). To date 19 of the 26 murine Ets factors have
targeted/phenotypic alleles listed in the Mouse Genome Informatics Database
(Blake, Eppig et al. 2006), a number of which demonstrate increased
apoptosis resulting from the lack of Ets gene expression (Hyams 1977;
Bories, Willerford et al. 1995; Muthusamy, Barton et al. 1995; Su, Chen et al.
1997). Collectively these results reveal an important, albeit often context
dependent, role for Ets factors in the regulation of cell survival.

1.1.2.2 Differentiation
Significant roles for Ets genes in cell differentiation have also been
documented. This is well demonstrated by differentiative defects of
hematopoiesis (Scott, Simon et al. 1994; Olson, Scott et al. 1995; Barton,
Muthusamy et al. 1998; Garrett-Sinha, Su et al. 1999; Hart, Melet et al. 2000;
Spyropoulos, Pharr et al. 2000; Walunas, Wang et al. 2000; Kawada, Ito et al.
2001; Lacorazza, Miyazaki et al. 2002; Costello, Nicolas et al. 2004; Hock,
Meade et al. 2004; Xue, Bollenbacher et al. 2004) or neurogenesis (Livet,
Sigrist et al. 2002; Hendricks, Fyodorov et al. 2003; Hippenmeyer, Vrieseling
et al. 2005; Sedy, Tseng et al. 2006) in Ets gene targeted mice (TABLE I).
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1.1.2.3 Cell Migration
Considerable evidence also supports a role for Ets factors in induction of cell
motility and expression of matrix remodeling genes to facilitate migration.
Examples of pro-migratory effects of Ets gene expression include SPDEF and
ELF3 in epithelial cells (Schedin, Eckel-Mahan et al. 2004; Gunawardane,
Sgroi et al. 2005), Ets1 in endothelial cells and neural crest (Iwasaka, Tanaka
et al. 1996; Tahtakran and Selleck 2003), ELK3 in fibroblasts (Buchwalter,
Gross et al. 2005), Yan and D-Ets4 (Drosophila Ets genes) in border cells
(Hsouna, Watson et al. 2004; Schober, Rebayet al. 2005) among others.
Interestingly, expression of SPDEF in epithelial tissues has also been
associated with decreased motility, presumably reflecting a dosage or context
dependent effect (Feldman, Sementchenko et al. 2003).

1.1.2.4 Regulation of Extracellular Matrix
The regulation of genes involved in extracellular matrix remodeling by Ets
transcription factors has been recently reviewed (Trojanowska 2000). A clear
role for matrix remodeling, by removing physical barriers to cell movement
and by regulating motogenic signals and their reception, in normal
(Stamenkovic 2003) and malignant (Friedl and Wolf 2003; Duffy 2004) cell
motility has been demonstrated. Examples of such regulation by Ets genes
include the regulation of MMP-1, 2, 3, 9, 13, uPA or TIMP-1 by Ets1 (Logan,
Garabedian et al. 1996; Nakada, Yamashita et al. 1999; Oda, Abe et al. 1999;
Quinn, Rajakumar et al. 2000; Reisdorff, En-Nia et al. 2002; Liu, Liang et al.
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2005; Bai, Wang et al. 2006; Baillat, Leprivier et al. 2006; Nelson, Subbaram
et al. 2006) and studies with in which Ets2 targeted mice demonstrated a
direct requirement for Ets2 in the expression of MMP-3, 9, and 13
(Yamamoto, Flannery et al. 1998). Ets genes are also implicated in the
regulation of cell surface adhesion proteins that promote migration when
expressed in tumor cells (Katabami, Kato et al. 2006).

1.1.2.5 Cell Senescence
Evidence supports a role for Ets 1 and Ets2 in the regulation of cell
senescence, with increasing Ets1 or Ets2 expression levels associated with
cell senescence (Ohtani, Zebedee et al. 2001; Krishnamurthy, Torrice et al.
2004; Ball and Levine 2005), while diminished Ets2 levels have also been
shown to be associated with cell senescence (Ohtani, Zebedee et al. 2001).
In all of these studies, Ets1 or Ets2 regulation of senescence was related to
transcriptional control of CDKN2a (alternately known as p161NK48) expression.
Another Ets factor in the same subfamily, Elk1, has been shown to be less
active in senescent cells. Senescence is associated with reduced
phosphorylation of Elk1, resulting in diminished Elk1 transcriptional activity
(Tresini, Lorenzini et al. 2001). Misregulation of Ets genes is also associated
with pathologies related to loss of regulation of these cellular processes. The
most encompassing example of such pathology is oncogenesis and cancer
progression, which requires increased cell division, resistance to apoptosis,
loss of differentiation, increased motility, and escape from senescence. While
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the largest body of evidence supports a role for Ets genes as protooncogenes, there is recent evidence that some may act as tumor suppressor
genes (Foos, Garcia-Ramirez et al. 1998; Seki, Suico et al. 2002; Feldman,
Sementchenko et al. 2003; Seth and Watson 2005; Yu, Xia et al. 2006).
Examples supporting a role for Ets genes as proto-oncogenes, include
increased expression of Ets genes in cancers of the Thyroid (Ets1/2) (de
Nigris, Mega et al. 2001), prostate (Erg) (Walsh 2006), breast (ETV1) (Goel
and Janknecht 2004), lung (ETV4), and gynecologic (ETV5) (Planaguma,
Abal et al. 2005) among many others.

1.2 Ets 1 Gene

1.2.1 Ets 1 Expression Pattern
The Ets1 gene is expressed in a temporal and tissue specific manner. Ets1
expression appears early in development; it is expressed in murine embryonic
stem cells and is expressed at high levels in the developing brain by
embryonic day 8 (E8) (Kola, Brookes et al. 1993). Early in development Ets1
expression is a marker of neural crest (Aybar, Nieto et al. 2003). Persistent
expression of Ets1 in lung and heart are observed from day E11.5 in the
mouse (Maroulakou, Papas et al. 1994). High levels of Ets1 are associated
with areas of epithelial-mesenchymal transition in the developing heart
(Fafeur, Tulasne et al. 1997; Maroulakou and Bowe 2000). Ets1 expression is
initiated at key time points in hematopoietic progression. Fetal liver expresses
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Ets1 from E11.5 to E13.5, coinciding with the initiation of fetal liver
hematopoiesis. Onset of Ets1 expression in the thymus is first detectable
around day E15.5, coincident with the switch from fetal to adult hematopoiesis
(Bhat, Komschlies et al. 1989). Among mature thymocyte subsets, CD4+CD8thymocytes show higher levels of Ets1 expression than CD4-CD8+
thymocytes. Mature resting T cells express high levels of Ets1, but Ets1
expression is markedly reduced in activated T cells, reciprocal to the
expression pattern of Ets2 (Bhat, Thompson et al. 1990). Ets1 expression in
spleen is seen from birth.

Less data is available to describe Ets1 isoform specific expression patterns.
For example, full-length Ets1 protein is expressed at approximately 40-fold
higher level compared to

Ets1~ VII

in astrocytes at the protein level

(Fleischman, Holtzclaw et al. 1995). Similar expression is seen in the stroma
and glandular epithelium of the endometrium, where full-length Ets1 is
expressed at significant levels, but

Ets1~VII

is only weakly expressed at the

protein level (Kilpatrick, Kola et al. 1999). It is not uncommon for published
reports to measure Ets1 expression based upon full-length protein only, or
transcript expression that fails to distinguish between isoforms. Of the reports
that distinguish between the two isoforms, a general consensus has emerged
that the full-length isoform is the most abundant form in cells where Ets1 is
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expressed. There is evidence however that in some cell-types

Ets1~ VII

protein may be the more highly expressed form, at least in some contexts
(Barton, Muthusamy et al. 1998).

1.2.2 Ets1 Isoforms and Functional Domains
Ets1 genomic structure is highly conserved in mouse and man. The Ets1
gene is located within a house-human syntenic region, with 11 q22.3-qter
(109.8-137.2 MB) corresponding to a region within mouse 9A4-9C (26.5-54.4
MB) in reverse orientation (Spyropoulos, Bartel et al. 2003). The mammalian
Ets1 gene is comprised of 8 exons, commonly designated A and III-IX, with
the nomenclature of the first exon reflecting the divergence in avian and
mammalian genomic structure (Jorcyk, Watson et al. 1991). The Ets1 gene
has been shown to produce multiple transcripts arising from differential
polyadenylation, multiple transcription initiation sites, and alternative splicing
(Collyn d'Hooghe, Galiegue-Zouitina et al. 1993; Bellacosa, Datta et al. 1994).
Alternatively spliced transcripts are derived from alternatively skipping exon
IV, exon VII, or exon IV and VII, with no disruption in reading frame (Jorcyk,
Watson et al. 1991). Though alternative splicing could be predicted to
generate at least four distinct Ets1 protein isoforms, only the exon VII splice
variant

(Ets1~ VII)

and the full-length Ets1 transcript are translated to form

detectable protein in chicken, mouse and human (Fig 1.3) (Koizumi, Fisher et
al. 1990; Jorcyk, Watson et al. 1991; Fisher, Koizumi et al. 1992). These
proteins are highly conserved across species, with 97% sequence identity
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A. Summary of Key Domains of Ets1 and Exon Structure
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B. Generation of Two Ets1 Isoforms by Alternative Splicing
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Figure 1.3 Ets1 Functional Domains and Alternative Splicing. A. Summary of
functional domains of full-length Ets 1 protein (top) with exons coding for these domains
pictured below (blue). CTI= C-terminal inhibitory domain . THR38= Threonine residue 38.
B. Generation of Two Ets1 Isoforms by Alternative Splicing. The mammalian Ets1 gene
produces two protein isoforms, Ets1 ~ VII (top) and full-length Ets1 (bottom), which arise
from alternative splicing of exon VII with no disruption in reading frame. The exon VII
coded domain is an autoregulatory domain of Ets1, containing phosphorylatable serine
residues . Key residues involved in autoinhibition are indicated in sequence inset.
Residues indicated in red are highly conserved and have been shown to be required for
full inhibition of DNA binding by the phosphorylation mediated pathway. PNT= Pointed
Domain, ETS DBD= Ets DNA Binding Domain, VII *RDE* = regulatory domain coded by
Exon VII, MAPK= Map kinase phosphorylation site, PKC= Protein kinase C
phosphorylation site.
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between human and mouse, and 94% identity between human and chicken
(p54) at the amino acid level (GenBank: P14921, P27577, P13474).
Functional domains of Ets1 are similarly conserved across species. Key
functional domains of Ets1 include the Ets domain, pointed domain,
transactivation domain, autoregulatory domain, C-terminal inhibitory domain,
as well as conserved phosphorylation sites for activation or inhibition, and a
nuclear localization sequence. The Ets domain, as previously discussed, is a
highly conserved wHTH DNA binding domain that defines the Ets family. The
Ets1 DNA binding domain is a typical Ets domain, distinguishable by the
sequence preference for 5'-RSMGGAHGYV-3' (Fisher, Mavrothalassitis et al.
1991), 5'-RCCGGAHGY-3' (Nye, Petersen et al. 1992), 5'-ACMGGAHRTT3' (Woods, Ghysdael et al. 1992), or 5'-CMGGAWRTT-3' (SELEX) (Hallikas,
Palin et al. 2006) beyond the core 5' -GGAW-3' consensus binding site,
depending upon analysis. An additional remarkable feature of the Ets1 DNA
binding domain is the presence of a nuclear localization sequence near the Cterminal end of the domain (Boulukos, Pognonec et al. 1989). However, given
that deletion of a domain N-terminal to the Ets domain enhances nuclear
localization of Ets 1, the ETS domain NLS is necessary but not sufficient for
nuclear localization, most likely reflecting regulation by steric hindrance about
the Ets domain (Koizumi, Fisher et al. 1990). Recently it has been shown that
a hydrophobic region of Ets1 between amino acids 121-131 contains a
nuclear export sequence which may account for the enhanced nuclear
localization of the N-terminal truncated form (Lulli, Romania et al. 2006). Ets1
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also contains a pointed domain. The structure of the Ets1 pOinted domain is
globular and consists of 5 a-helixes, distinguishing it (and GABPa) from other
factors like Tel and Fli1 that have only 4 a-helixes (Slupsky, Gentile et al.
1998; Mackereth, Scharpf et al. 2004). The Ets1 pointed domain is also
distinguished by its monomeric solution structure, as it fails to form homo- or
hetero-dimers with the pointed domains of other Ets factors (Mackereth,
Scharpf et al. 2004). Additionally Ets1 and Ets2 uniquely contain a docking
site for Erk2, not found in the structurally similar GABPa pOinted domain,
required for RAS-mediated augmentation of transcriptional activity (Seidel
and Graves 2002). Mechanistically this is accomplished by phosphorylation of
a conserved threonine residue at position 38 (THR38) of Ets1. This threonine
residue is unique to the pointed domains of both Ets1 and Ets2, and in both
proteins phosphorylation of this residue is known to increase transcriptional
activity (Yang, Hauser et al. 1996; Wasylyk, Bradford et al. 1997). Just Nterminal to this site, Ets1 has a consensus sumoylation motif allowing for
SUMO to be attached to LYS15 (Macauley, Errington et al. 2006). The
mammalian Ets1 gene contains a single transactivation domain, located
between the pointed domain and the Ets domain. This is a distinction from the
avian Ets1 gene which may include an additional N-terminal transactivation
domain in the p68 isoform (Albagli, Flourens et al. 1992; Albagli, Soudant et
al. 1994). The mammalian Ets1 transactivation domain acts by direct
interaction with CBP and p300 (Yang, Shapiro et al. 1998; Jayaraman,
Srinivas et al. 1999), in a mechanism requiring the pointed domain, and
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augmented by phosphorylation of THR38 (Foulds, Nelson et al. 2004). The
remaining two domains are both modulators of Ets1 activity, at least in part by
regulating Ets1 DNA binding. The C-terminal repression domain of Ets1
exhibits homology to Ets2 and directly interferes with DNA binding (Hagman
and Grosschedl 1992); deletion of this region increases binding 20 to 50 fold
and this sequence is inverted in the oncogenic E26 retrovirus (Hagman and
Grosschedl 1992; Lautenberger and Papas 1993).

The domain encoded by exon VII and has been identified as a negative
regulator and modulator of DNA binding, a mediator of homo- and heterotypic
protein-protein interactions, and a target of calcium mediated
phosphorylation/autoinhibition (Fisher, Fivash et al. 1994; Rabault and
Ghysdael 1994; Kim, Sieweke et al. 1999; Cowley and Graves 2000; Baillat,
Begue et al. 2002). The presence or absence of this domain is the sole
distinguishing feature between full-length Ets1 and the naturally occurring
splice variant Ets1AVII. Collectively exon VII domain-specific activities allow
Ets1 isoforms to differentially modulate Ets1 target genes. For example, exon
VII mediated homotypic and RUNX1-Ets1 heterotypic protein-protein
interactions augment transcription of MMP-3 and CSF2 respectively (Baillat,
Begue et al. 2002; Liu and Grundstrom 2002; Liu, Holm et al. 2004).
Conversely, other target genes such as VE-Cadherin are transcriptionally
activated more strongly by the Ets1AVil variant (Lionneton, Lelievre et al.
2003). Significantly these distinctions are physiologically relevant, ectopic
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expression of the

Ets1~ VII

isoform but not the full-length isoform in DLD-1

cells restored FAS mediated apoptosis demonstrating functional distinction of
these isoforms (Li, Pei et al. 1999). A similar pro-apoptotic role for

Ets1~VII

has been suggested for invasive breast cancer cells (Ballschmieter, Braig et
al.2003).

1.2.3 Ets1 Autoinhibition
One of the key regulatory functions of the exon VII coded domain, and key
distinction between Ets1 isoforms, is autoregulation of Ets1 transcriptional
activity. The exon VII coded domain alters the affinity and avidity of full-length
Ets1 for its cognate DNA binding site, allowing for more rapid binding but 4-20
fold reduction in avidity (Fisher, Fivash et al. 1994). More exquisite regulation
of Ets1 activity is provided by post-translational modification of the exon VII
domain, which allows for more specific, rapid, and larger magnitude reduction
in Ets1 transcriptional activity. Upon phosphorylation of the full-length Ets1 by
calcium-calmodulin kinase II (CamK II), a calcium activated kinase, DNA
binding is rapidly abrogated while

Ets1~VII,

which lacks such sequences, is

not phosphorylated and remains uninhibited (Rabault and Ghysdael 1994;
Cowley and Graves 2000). Thus Ets1 activity in response to calcium signaling
is modulated by the balance between full-length and ~ VII isoform expression.
Recent studies have provided significant insight into the mechanism of exon
VII mediated inhibition of Ets1 DNA binding (Fig 1.4). The secondary structure

18

l\'l odel of Phosph()r~'lation-Dcflcndcnt Inhibition of D:\ .~
N246

Bindin~

PII0 Sr IlO RHxn :o

N246

'.\

.....: ~..-- 1,

~

~ , ,~~s c
,-,.
....

( . a kilH'~

HI-I

-?"

Figure 1.4 Mechanism of Exon VII Mediated Inhibition of DNA Binding. The
auto-inhibitory domain exists in a conformational equilibrium between DNA
binding permissive and inhibited states. This conformational change is
dependent upon the stabilization or dissolution of Helix HI-1. Upon
phosphorylation of the exon VII coded domain by CamK II, HI-1 is stabilized
dramatically shifting the equilibrium to the DNA binding inhibited state. The
phosphatase calcineurin dephosphorylates the exon VII coded domain,
increasing DNA binding of full-length Ets1.
Adopted from Cowley DO and Graves 8J; Genes Dev. 14: 366-376, 2000
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of the exon VII domain is in equilibrium between an inhibited state consisting
of four helices and a DNA-binding permissive state in which the helix HI-1
(inhibitory helix1 ) melts into a random coil (Garvie, Pufall et al. 2002; Lee,
Donaldson et al. 2005). In the permissive state, protease cleavage sites
normally masked by HI-1 become exposed, potentially providing an
alternative method for inhibiting Ets1 activity. The equilibrium is not predicted
to appreciably favor either product in the absence of post-translational
modification or protein-protein interactions. Physiological events that trigger
an increase in intracellular calcium concentration, such as ligation of the T cell
receptor, promote phosphorylation of the exon VII domain. Specifically,
phosphorylation of the serine residues 5251,5257,5282, and 5285 is
sufficient to stabilize the helical structure HI-1 (Liu and Grundstrom 2002).
More recently it has been shown that 5251,5282, and S285 are the critical
phosphate-acceptors; the mutation of anyone of these dramatically reduces
DNA binding inhibition and combinatorial mutation produces a graded effect
(Pufall, Lee et al. 2005). In the phosphorylated state the exon VII domain
reduces the DNA binding activity of Ets1 by an additional -50-fold by
dramatically altering the stability of the DNA-binding inhibited conformation
(Rabault and Ghysdael 1994; Cowley and Graves 2000), constituting a total
activity reduction of 500- to 1000-fold by the activated ~ VII domain (Pufall,
Lee et al. 2005).
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1.2.4 Ets1 Protein-Protein Interactions
Given that the Ets family consists of a relatively large number of transcription
factors competing for binding on short recognition sequences which allow for
promiscuous binding, specificity of Ets transcriptional activity must be
regulated by factors beyond simple sequence recognition. While specificity of
Ets gene activity is directed by many different modes of regulation, differential
protein-protein interactions are among the most significant (Graves and
Petersen 1998; Li, Pei et al. 2000; Dittmer 2003). Ets1 activity is regulated
both positively and negatively by protein-protein interactions. More
importantly, many of these regulatory protein-protein interactions require the
exon VII domain further distinguishing the functional capabilities of the two
isoforms of Ets1 (Fig 1.5). Proteins that bind the Ets1 exon VII domain act to
enhance transcriptional activity on specific promoters. These interactions
include RUNX1 on TCRa, TCRP, osteopontin and CSF2 promoters, where
juxtaposed RUNX and ETS DNA binding sites allow the exon VII domain of
full-length Ets1 to directly interact the 'Negative Regulator of DNA Binding'
(NRDB) of Runx1 providing for mutual activation and synergistic
transcriptional activity (Wotton, Ghysdael et al. 1994; Giese, Kingsley et al.
1995; Sato, Morii et al. 1998; Kim, Sieweke et al. 1999; Goetz, Gu et al. 2000;
Gu, Goetz et al. 2000). The Ets1 exon VII domain similarly partners with the
HIF-2a carboxy-terminus, where coordinated 'hypoxia response element'
binding sites (HRE) are juxtaposed with ETS binding sites, as illustrated by
transcriptional synergy on the FLK1 promoter (Elvert, Kappel et al. 2003).
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Stabilization of DNA Binding By Protein Partnering of the
Exon VII Coded Domain
A

N
D

RBS

N

EBS

EBS

GM-CS F Promoter

EBS

MMP-3 Promoter

Figure 1.5 Stabilization of Ets1 DNA Binding by Exon VII Domain-Protein
Interactions. Homotypic and heterotypic interactions about the exon VII coded
domain affect Ets1 DNA binding stability. A. RUNX1 is a modular protein with an
autoinhibitory NRDB (Negative Regulator of DNA Binding) that is capable of
inhibiting the RUNT DNA binding domain from contacting DNA. B. Full-length
Ets1 contains an autoinhibitory domain coded by exon VII that blocks the Ets
domain from binding DNA in the repressed state. C. Heterotypic and mutual
release of autoinhibition of Ets1 and RUNX1 by protein partnering on the CSF2
promoter. D. Homotypic protein partnering mediated by the exon VII coded
domain of Ets1 relieves autoinhibition of Ets1 on the palindromic ETS binding
sites (EBS) of the MMP-3 promoter. RBS= Runx1 Binding Site, EBS= Ets
Binding Site, NRDB= Negative regulator of DNA binding domain of Runx1 ,
RUNT= Runx1 DNA binding domain, N= N-terminus, C= C=Terminus, ETS= Ets
DNA binding domain, VII= regulatory domain coded by Exon VII of Ets1.
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Such synergy has also been demonstrated in exon VII domain-PIT-1
homeodomain (Pthd) interactions, where binding sites up to 28 nucleotides
away could allow for synergistic transcription in vitro, but did not seem to be
required in vivo on the prolactin promoter (Augustijn, Duval et al. 2002; Duval,
Jean et al. 2003). The reason for the discrepancy in in vivo vs. in vitro
requirements may reflect more robust regulation in vivo where multiple layers
of regulation confer functional redundancy, or higher stringency (less-optimal)
conditions in vitro; alternatively it may indicate that the PIT-1/ETS1
cooperativity does not require direct interaction with the exon VII domain in
vivo. The in vivo PIT-1/ETS1 interaction could be verified by chromatin
immunoprecipitation to address this issue. When two EBS are juxtaposed on
a promoter sequence, such as that of MMP-3, full~length Ets1 can form
dimeric homotypic interactions with the exon VII domain to synergistically
augment transcription (Baillat, Begue et al. 2002).

While these interactions have all exerted their effect by direct binding of the
exon VII domain, SP100 is an Ets1 protein partner that interacts with both Nterminal and C-terminal regions to activate Ets1 on the CSF2 promoter
(Wasylyk, Schlumberger et al. 2002) in an exon VII domain dependent
manner. However, SP100 has been shown to repress Ets1 activity on other
promoters (Yordy, Li et al. 2004; Yordy, Moussa et al. 2005). Given that the
CSF2 promoter contains palindromic Ets binding sites, this suggests the
intriguing possibility that SP1 00 acts as an obligate negative regulator of Ets1
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activity and escape from this repression is only possible via protein partnering
involving the exon VII domain. That is, SP100 blocks full-length Ets1 activity
only when monomeric and Ets1 ~ VII at all times. In this model 'activation'
would represent the effective removal of

Ets1~VII

from competition for binding

to the palindromic EBS sequence. On coordinate/palindromic EBS,
synergistic transcriptional activity is only possible when both sites are
occupied by full-length Ets1. If SP1 00 acts to destabilize Ets1 transcriptional
complexes, but full-length Ets 1 is resistant to this process, a net increase in
transcription would result from increased dimeric (a synergistic transcriptional
effect) full-length Ets1 occupancy of this promoter.

Apart from SP100, other known heterotypic protein interactions involving the
exon VII domain are those which result in post-translational modifications of
full-length Ets1. These include calcium sensitive regulation by CamK II and
calcineurin, which bind Ets1 to phosphorylate and dephosphorylate serine
residues of the exon VII domain inhibiting and releasing inhibition,
respectively (Rabault and Ghysdael 1994; Cowley and Graves 2000). Protein
Kinase C-alpha (PKCu) binds Ets1 and is able to phosphorylate the serinerich exon VII domain in a Ca 2+ independent manner. Surprisingly this posttranslational modification is able to enhance Ets1 transcriptional activity rather
than repress it on the PTHrP P3 promoter (Lindemann, Braig et al. 2003).
While the possibility remains that expression of constitutively active PKCu
acts to increase Ets1 transcriptional activity on the PTHrP promoter by
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indirect means (targets other than Ets1) it is also possible that direct
phosphorylation of Ets1 exon VII domain may favor coordinated proteinprotein interactions with an Ets1 protein partner to augment transcription.

As might be expected among such a large family of genes as the Ets family,
the majority of the known protein-protein interactions involve binding to the
most conserved domain, the Ets domain. The majority of these favor Ets1
binding to its recognition sequence (Dittmer 2003). Examples include Pax5
which allows Ets1 to bind non-canonical EBS sites 5'-GGAG-3' on the B-cell
Mb1 promoter; Ets/Pax coordinate DNA complex structure has been studied
by x-ray crystallography (Wheat, Fitzsimmons et al. 1999; Garvie, Pufall et al.
2002; Maier, Colbert et al. 2003). Another common interaction partner that
directly binds the Ets domain is AP-1, which has been shown to partner with
Ets1 onTIMP-1, MMP-1, MMP-3 and CSF2 promoters among others (Bassuk
and Leiden 1995; Logan, Garabedian et al. 1996; Thomas, Tymms et al.
1997; Nelson, Subbaram et al. 2006). As no evidence is currently available,
these protein partners can only be presumed to similarly interact with fulllength and

~VII

isoforms of Ets1.

1.2.5 Ets1 Knockout Mice
Targeted disruption of Ets1 in mice, which deletes both isoforms, results in
perinatal lethality of unknown cause. Surviving mice and chimeras derived
from Ets1 targeted cells exhibit pan-lymphoid defects. These defects include
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reduced numbers of thymocytes, lymphoid cells in the spleen, NK and NKT
cells, loss of detectable NK and NKT cell activity, decreased proliferation and
elevated apoptosis in mature T cells, increased differentiation of B-cells to
plasma cells with elevated serum IgM, B-cell receptor signaling defects,
abnormalities in TCR J3-selection in thymopoiesis, and ineffective Th1
response (Bories, Willerford et al. 1995; Muthusamy, Barton et al. 1995;
Barton, Muthusamy et al. 1998; Walunas, Wang et al. 2000; Eyquem, Chemin
et al. 2004; Eyquem, Chemin et al. 2004; Grenningloh, Kang et al. 2005).
Complicating the assessment of Ets1 function, one of the two lines of Ets1
targeted mice previously reported as a null allele (and the only line
successfully generated without chimera complementation) has recently been
revealed to produce low levels of a neomorph lacking the pointed domain of
Ets1 (Wang, John et al. 2005). This greatly confounds interpretation of Ets1
phenotypes since absence of Ets1 function can not be assured as the
neomorph would be expected to retain DNA binding and transactivation
domains. Moreover, the pointed domain is a key regulatory domain of Ets1 ,
and the effects from specific deletion of this domain are uncertain.

1.3 Thymopoiesis

1.3.1 Thymus Organogenesis
In the mouse, thymus organogenesis occurs between days E10 and E13.5
(Manley and Blackburn 2003). Lineage analysis and transplantation studies
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suggest that the thymic epithelial anlage is derived entirely the endodermal
lining of the third pharyngeal pouch (Bogden, Haskell et al. 1979; Bennett,
Farleyet al. 2002; Gill, Malin et al. 2002; Gordon, Wilson et al. 2004).
Consensus has been long established that the mesenchyme of the
developing thymus is neural crest cell (NCC) derived, and eventually gives
rise to the capsule and perivascular tissues and possibly intrathymic
mesenchymal cells with fibroblast like morphology (Jiang, Rowitch et al. 2000;
Suniara, Jenkinson et al. 2000; Manley and Blackburn 2003; Blackburn and
Manley 2004). After the early thymus is formed (E11-E11.5), it is seeded with
hematopoietic progenitor cells, which populate the organ prior to
vascularization (Wilkinson, Owen et al. 1999). Around day E14
vasculogenesis begins, with endothelial cells and peri endothelial tissue
contributed by neural crest mesenchyme (Le Douarin, Dieterlen-Lievre et al.
1984).

1.3.2 Thymus Function
The thymus is a primary hematopoietic organ in adult hematopoiesis by virtue
of its role in T-cell development. T-cell development in the thymus,
thymopoiesis, is the spatially and temporally restricted sequence whereby
pluripotent hematopoietic precursor cells give rise to the differentiated T-cell
lineages with non-self reactive but diverse antigen receptor repertoire.
Structurally the thymus is divided into two major histologically identifiable and
functionally distinct compartments: the cortex and the medulla. Stages of
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thymopoiesis occur in discrete compartments of the thymus and the cortex
can further be subdivided into 4 sub regions based upon this functional
distinction (Fig 1.6) (Lind, Prockop et al. 2001; Blackburn and Manley 2004).
In contrast to previous studies that indicated that thymic progenitor cells home
to the subcapsular zone of the thymus (Penit 1988), Lind et a/ demonstrate
that progenitors home to the cortico-medullary zone and differentiate in a
coordinated manner through migration to the subcapsular zone and back to
the medulla. Immuno-phenotyping of thymocyte subpopulations has allowed
the step-wise progression of thymocyte development to be delineated.
Classically this progression is described based upon the presence or absence
of CD4 and CD8 antigens in sequence of increasing maturity: double negative
(DN), double positive (DP), and each single positive lineage (CD4, CD8). The
DN cells are further subdivided based upon presence or absence of CD44
and CD25 antigens into CD25- CD44Hi (DN1) CD25+CD44 Hi(DN2)
CD25+CD44 10 (DN3) and CD25-CD4+CD8+(pre-DP) (Wu, Antica et al. 1991;
Wu, Li et al. 1996). The earliest thymocytes, DN1, are a heterogeneous mix
of precursor cells capable of differentiating into T-cells but differing in their
ability to contribute to NK, B, and myeloid lineages (Porritt, Rumfelt et al.
2004; Weerkamp, Baert et al. 2006). These cells are concentrated at the
cortico-medullary junction of the thymus (cortical zone 1, Fig 1.6) CD24+ and
CD24 10 (Heat stable antigen) DN1 cells give rise to proliferative DN2 cells
which are T -lineage specified but not committed as they retain potential to
generate NK cells, dendritic cells, and macrophages. The DN2 stage is the
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Figure 1.6 Histological and Functional Compartmentalization of the
Thymus. Stages of thymopoiesis occur in distinct compartments of the thymus.
These include 4 cortical regions (Region1-4, indicated left) and the medulla.
More detailed description of thymopoiesis and these compartments are provided
in the text. Figure adopted from (Lind, Prockop et al. 2001).
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last TCR-independent stage of development, with the DN2 to DN3 transition
is marked by turning on recombination activating genes (RAG), expression or
pre-TCRn, and activation and rearrangement at

TCR~,

y, and 8 loci (Godfrey,

Kennedy et al. 1993). DN3 cells are committed to the T-lineage. They
undergo J3-selection, a process where cells successfully rearranging the TCR~

survive, proliferate and differentiate into DN4/pre-DP cells by initiation of

pre-TCR signaling (Godfrey, Kennedy et al. 1993). In the DN4 stage

~

selected cells undergo a proliferative expansion and further differentiate into
DP cells and RAG genes are no longer expressed. These cells are located in
the subcapsular zone of the thymus (cortical zone 4, Fig 1.6). RAG genes
are re-expressed in DP thymocytes and TCRn is rearranged. Positive
selection, in which cells that have undergone successful TCR rearrangement
proliferate and differentiate, occurs at this stage. DP cells ultimately
differentiate into either CD4 or CDB single positive thymocytes, though the
mechanism by which TCR Signaling regulates this process is not completely
understood. CD4 and CDB thymocytes undergo negative selection in which
cell recognizing self-antigens are stimulated to undergo programmed cell
death. In the final stage of thymopoiesis surviving CD4 and CDB single
positive thymocytes emigrate from the thymus into peripheral circulation.

1.3.3 Clinical Thymomegaly
Thymic hyperplasia, an excessive proliferation of cells, may be broadly
classified into two clinically designated types: so called 'true hyperplasia' and
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Iymphofollicular hyperplasia. These are distinguishable based upon the
presence or absence of Iymphfollicles with germinal centers in the medulla
(Hofmann, Moller et al. 1987; Ricci, Pescarmona et al. 1989). True
hyperplasia, which is hyperplasia of the thymus epithelium and lymphoid cells
without disruption of normal organ structure, is rare possibly because it may
be clinically asymptomatic until thymic mass is large enough to adversely
affect other organs, (e.g. respiratory distress) (Tareen, Hussain et al. 2001),
or difficult detection (Bogot and Quint 2005). It is more common in children
and young males, is not associated with autoimmune disease, and may be
associated with respiratory distress and peripheral blood lymphocytosis
(Ricci, Pescarmona et al. 1989). In younger patients thymic hyperplasia may
result from a rebound effect during recovery from immunosuppressive
stresses such as following chemotherapy (Mishra, MeHnkeri et al. 2001;
Sehbai, Tallaksen et al. 2006) or following severe burn (Hofmann, Moller et
al. 1987). Thymic hyperplasia has also been associated with other disease
conditions such as sarcoidosis (Pardo-Mindan, Crisci et al. 1980),
hypothyroidism (Yulish and Owens 1980), or thyrotoxicosis (Pendlebury,
Boyages et al. 1992). True hyperplasia is usually treatable by corticosteroids.
Lymphofollicular thymic hyperplasia is associated with chronic infection,
endocrine disorders, or autoimmune disease such as myasthenia gravis,
scleroderma, or rheumatoid arthritis (Hofmann, Moller et al. 1987). The
numerous hyperplastic lymph follicles which define Iymphofollicular
hyperplasia are comprised of T-lymphocytes and infiltrating B-Iymphocytes
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bearing markers similar to follicular mantle-zone lymphocytes (Hofmann,
Momburg et al. 1988).

1.4 Homeostatic proliferation

1.4.1 Introduction and Overview
In the peripheral lymphoid compartment (spleen, lymph nodes, and peripheral
blood), cell division and apoptosis are regulated to exert strict homeostatic
control on the absolute number of lymphocytes. Experimental examples of
such regulation are the recovery of lymphocyte populations to normal
numbers following experimentally induced leukopenia (Fry, Christensen et al.
2001) or antigen driven expansion (O'Flaherty, Wong et al. 2000). In the first
example, recovery involves the expansion of peripheral lymphocyte numbers;
and in the second example, recovery involves the reduction of these
numbers. These examples underscore that lymphocyte homeostasis can
control the balance between an insufficient number of cells to mount an
immune response and the excessive proliferation and/or over stimulation of
an immune response associated with pathological conditions such as cancer
and autoimmunity. In the first example, lymphopenia, antigen independent
proliferation of cells expressing memory cell markers (CD44Hi , CD122, Ly6C )
leads to recovery of normal or near normal lymphocyte numbers (MuraliKrishna and Ahmed 2000). Such homeostatic proliferation occurs from the
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expansion of preexisting memory cells, or from na'ive cells that acquire
memory cell characteristics (Tanchot, Lemonnier et al. 1997; Kieper and
Jameson 1999). This process requires normal thymopoiesis to establish a
competent na'ive pool- that expresses the required cytokines (e.g. IL-7) and
has the ability to upregulate the genetic program( s) required for the memory
cell phenotype. In the second example, antigen driven expansion, clonal
expansion of antigen stimulated cells is limited by extrinsic apoptotic
pathways (receptor mediated) when antigen loads are high (Lenardo 1996).
This antigen expanded pool of cells is diminished by intrinsic apoptotic
pathways (cytokine withdrawal) at the resolution of the immune response (low
antigen stimulation) to return the peripheral lymphocyte pool to normal size
(Lenardo, Chan et al. 1999).

1.4.2 Clinical Significance
Homeostatic proliferation in the peripheral lymphoid compartment is
fundamental to the maintenance of an effective immune system.
Conceptually, this process is clinically relevant in conditions where either a
pathological deficiency or a pathological expansion of immune cells occurs,
and in the modulation of the balance between tolerance and autoimmunity.
Examples of pathological deficiencies include Iymphopenias induced as result
of therapy (e.g. chemotherapy for cancer) or pathological immunodeficiency
such as found in patients with acquired immunodeficiency syndrome. Immune
reconstitution in patients with lymphopenia is challenging and has not been
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met with great success. Even the infusion of large numbers of progenitor cells
is not sufficient to restore T-cell immune competence (Mackall, Stein et al.
2000), and very poor recovery of immune function or vaccine response
occurs, for example, even beyond one year in post-stem cell transplantation
cases (Lum 1987). These deficiencies represent, at least in part, differences
in of peripheral homeostatic vs. thymic means (Roux, Dumont-Girard et al.
2000). Leukemia is a good example of pathology where loss of normal
homeostatic constraints on the size of the peripheral lymphocyte pool results
in pathology. As mentioned previously, mature lymphocytes require either
antigen challenge or cytokine stimulation to proliferate. Furthermore, maximal
expansion of these cells is strictly limited by availability of antigen or
cytokines. Loss of these homeostatic controls in mature lymphocytes may
lead to chronic lymphocytic leukemias.

In addition to regulating the size of the peripheral lymphocyte pool, peripheral
homeostatic proliferation exerts influence over the regulation of antigen
receptor diversity and activation threshold. This is clinically significant in
maintaining self-tolerance to avoid autoimmunity, as well as in the ability to
mount an effective anti-tumor response based upon tumor-specific antigens
for which tolerance exists. Effective anti-tumor immune response is at least in
part due to tolerance to the self antigens expressed by tumor cells. Acute
homeostatic proliferation offers a means by which expansion of cells based
upon self-antigens may allow for tolerance to be broken, as proliferation
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depends at least in part upon stimulation by self-antigen MHC complexes
(Ge, Rao et al. 2001; Kassiotis, Zamoyska et al. 2003; Ge, Bai et al. 2004).
This exemplified by the generation of anti-tumor response to challenged mice
following sub-lethal irradiation (Dummer, Niethammer et al. 2002; Baccala,
Gonzalez-Quintial et al. 2005). While this mechanism is of benefit in the
modulation of immune response versus malignancies, it may be deleterious
when it results in autoimmunity (King, llic et al. 2004).
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Chapter 2: Generation of Allelic Series of Ets1 Mutant Mice
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2.1 Introduction

2.1.1 The Mouse as a Model System
The selection of a model system for the genetic analysis of traits, using either
classical or reverse approaches, is dependent upon both pragmatic and
theoretical considerations. Such constraints have lead to the generation of
well established model systems; among the best characterized metazoan
genetic model systems are Caenorhabditis e/egans, Mus musculus,
Drosophila melanogaster, and Dania rerio, each having particular strengths
and limitations (van Heyningen 1997; Pradel and Ewbank 2004). In order to
determine the in vivo function of Ets1 isoforms, Mus Musculus is the clear
model of choice. Key advantages of the mouse include its similarity to Homo
sapiens, and established methods for engineering precise mutations by gene
targeting. While comparative analysis of the mouse and human genomes has
revealed the murine genome to be approximately 14% smaller, the genomes
are highly similar with respect to functional elements, containing an estimated
30,000 genes arranged in similar linear order (90 0/0 partitionable into syntenic
blocks) (Waterston, Lindblad-Toh et al. 2002). This similarity includes the Ets
transcription factor family, with 26 of 27 Ets genes having murine orthologs
and no murine Ets genes lacking a human ortholog (Maglott, Ostell et al.
2005). This diversity is lacking in other model organisms. Drosophila, for
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instance, have as few as eight Ets orthologs (Hsu and Schulz 2000) and only
12 Ets genes have been annotated in the first draft of the Gallus genome
sequence (Hillier, Miller et al. 2004). Furthermore, this genomic similarity
predictably extends to physiological similarities. For instance mice are
susceptible to a similar range of pathogens as humans, and the immune
response elicited contains both rapid innate and memory-generating adaptive
responses analogous to humans (Buer and Balling 2003). This contrasts with
the innate only response in metazoans more primitive than jawed vertebrates
(Agrawal, Eastman et al. 1998). The significance of this is underscored by the
observation that the most common defects reported in Ets gene targeted mice
relate to hematopoiesis/immune or neurological defects (Bartel, Higuchi et al.
2000). The mouse also holds the distinction of being the first metazoan model
system in which precise genetic alterations may be introduced by gene
targeting (Thomas and Capecchi 1986; Thomas, Folger et al. 1986). While
the recent advances have allowed for introducing such mutations in other
model organisms (Fan, Alestrom et al. 2004; Venken and Bellen 2005; Fan,
Moon et al. 2006), the mouse remains the most established and amenable
metazoan model for such studies.

2.1.2 Characterization of Ets1 Genomic Structure
The recent publication of human (Lander, Linton et al. 2001; Venter, Adams
et al. 2001) and mouse (Waterston, Lindblad-Toh et al. 2002) draft genome
sequences are landmark achievements in molecular genetics which promise
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to greatly accelerate the pace and scope of discovery in the post-genomic
era. Prior to this, genomic sequence was scantly available and investigation
requiring knowledge of genomic structure required de novo generation of this
fundamental information. While base by base sequencing may have been
regarded as the gold standard for such analysis, it was limited in application
due to considerations of cost and throughput (Hawkins, McKernan et al.
1997). Given that manipulations of genetic sequences by recombinant DNA
technology has classically been dependent upon the use of restriction
enzymes (Jackson, Symons et al. 1972; Cohen, Chang et al. 1973),
restriction mapping of sequences has been commonly used for determining
genomic structure when sequencing was not practicable (Tartof and Hobbs
1988). Although the C57BI/6 genome has been sequenced, other inbred
strain genomes including the most commonly used strain for gene targeting
(129/Sv) have not been completed. This limitation in availability extends to
BAC genomic clones. Consequently, we used traditional methods and
isolated

two Ets1 genomic clones from an isogenic library (Stratagene; strain

129/SVJ) using an Ets 1 cDNA probe. The genomic structure of isolated
clones was determined by classical restriction mapping, complimented by
eDNA/exon hybridization and limited sequencing (Fig 2.1). The larger of the
two clones (clone 8) spanned approximately 18 kb. This clone was found to
contain exons V, VI, and VII on its 5' end (6kb), and 12kb of intron VII on its 3'
end, as determined by hybridization and sequencing. The other clone (clone
14) spanned 11 kb of sequence, partially overlapping with clone 8, but shifted
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Figure 2.1 Determination of Ets1 Genomic Structure by Restriction Mapping. Two clones (#8 and #14) were isolated
frorn a 129SV genomic library and genomic structure 'Nas determined by restriction tllapping. TV= targeting vector. Fg=
fragment

more 5' to include exons III to VII. Comparison of this mapping (129/Sv strain)
to published genomic sequence (C57BII6) reveals differences in the
distribution of restriction endonuclease cleavage sites (Fig 2.2). This most
likely reflects strain specific differences of the C57BI/6 genomic sequence
relative to the 129/SVJ-derrived genomic restriction maps in the form of point
mutations in non-conserved sequences. These 129/Sv restriction maps
generated were used in the design of targeting vectors and analysis of gene
targeting and recombination events.

2.2 Generation of Ets 1AVII Mice

2.2.1 Design and Construction of a Targeting Vector
Based upon our previously determined genomic structure of the Murine Ets 1
locus, we designed a targeting vector to delete exon VII, so that resultant
alleles would be incapable of generating the full-length (unspliced) isoform of
Ets1 (Fig 2.3). A sequence replacement targeting vector was generated by
inserting an Apal adapter containing a loxP element into a unique Apal site in
intron VI 400 bp 5' to exon VII. A positive selectable neomycin
phosphotransferase (Neo) cassette with a 5' LoxP element was inserted in
reverse orientation into a unique Clal site 1.4kb 3' to exon VII. The LoxP-Neo
cassette consisted of the neomycin phosphotransferase gene under the
transcriptional control of the RNA polymerase II (Pol II) promoter with the last
exon and polyadenylation (PolyA) signal of the HPRT gene on its 3' end for

41

Comparison of Restriction Mapping With Genomic Sequence
III

Exons

IV

V

VI

VII

I

•

ri

_M
0

.c:

><s
_M
CO

.c

><

S

_M

.c:

Q.

(/)s
_M
s:::

Q.

~s

=M

"C

s:::

J:S
~M
0

~S

*

-M
a:
0

(.)

wS

=

M

C)

lOS

*

i:M
E

~S
0

5000

10000

15000

20000

Base Pairs
Figure 2.2 Genomic Structure of Murine Ets1 by Restriction Mapping and
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BamHI, C= Clal, N= Notl, and X= Xhol. Primer binding sites are indicated by
numbered arrows (p1, p2, p3). 3' Flanking probe and 10.5kb wild type BamHI
fragment are indicated. Second from top shows the structure of the Ets1~ VII
targeting vector. A 10xP element (black triangle) was cloned into a unique Apal
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shows the structure of the Cre conditional Ets1~VII targeted allele. The
reduction in size of the 3' BamHI fragment is indicated. Bottom depicts Cre
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efficient transcriptional termination (Spyropoulos, Pharr et al. 2000). The
entire Pol 11- Neo- PolyA sequence is flanked by the 10xP Cre-recombinase
recognition sequences when incorporated together with the 10xP element
inserted in the Apal site 5' to exon VII. This design allows for excision of exon
VII and the Neo Cassette upon cre-mediated recombination. Previous
studies have suggesteq that high targeting efficiency is achieved by the use
of isogenic DNA, and inclusion of homologous flanking sequence of 1Okb or
greater (Deng and Capecchi 1992). Accordingly, the Neo cassette is flanked
by approximately 10 kb and 5 kb of Ets1 129/SVJ isogenic sequence at its 5'
and 3' ends, respectively. Therefore by our strategy targeted alleles should
generate both full-length and 1\VII transcripts, and upon Cre-mediated
recombination, excise exon VII and the Neo cassette such that the targeted
recombined allele is only capable of generating Ets1 1\VII transcripts. For the
studies presented, cre-mediated recombination was conducted in targeted ES
cells and mice were generated from such targeted/Cre-recombined ES cells.

2.2.2 Identification of Targeted ES cells
The targeting vector was linearized with Not I restriction endonuclease and
electroporated into TC1-10 ES cells, which are derived from 129 strain mice
isogenic to the targeting construct (129/SvEvTac). Electroporated ES cells
were cultured on mitotically inactivated mouse embryonic 'feeder' fibroblasts
and treated with G418 for positive selection of cells that have incorporated the
Neo cassette into their genome and express the neomycin
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phosphotransferase gene. Drug-resistant ES cell clones were expanded,
genomic DNA isolated from aliquots of cells and screened for homologous
recombination by Southern blot analysis. As seen in Fig 2.3, the homologous
recombination of the

Ets1~ VII

targeting vector results in the inclusion of an

additional BamHI recognition site from the Neo cassette in intron VII of Ets1.
Therefore, Bam HI digestion of genomic DNA can be used to distinguish wild
type from targeted alleles by the down shift of the 10.5 kb wild type SamHI
fragment to a 6.7kb fragment in targeted alleles, when hybridized with a probe
from sequence flanking the 3' end of targeting vector homology. Targeted
alleles were detected in 22 of 97 G418 resistant ES cell colonies (22.7 %

),

recognizable by the presence of both 10.5kb and 6.7kb bands (Fig 2.4).

2.2.3/n vivo and In vitro Recombination of the Targeted Allele
The use of conditional alleles allows for the precise spatial and temporal
induction of genetic modifications in vivo (Lewandoski 2001; Sockamp,
Maringer et al. 2002). While this is among the most enabling tools available in
molecular genetics, it introduces the added consideration of the strategy for
induction of recombination. Among the considerations are the choice of the
Cre/LoxP or Flp/FRT recombinase system(Hoess, Ziese et al. 1982; McLeod,
Craft et al. 1986) or variations of these systems (Bode, Schlake et al. 2000;
Branda and Dymecki 2004) in vivo or in vitro recombination, and constitutive
vs. regulatable recombination. There is an ever expanding selection of 'driver'
lines of transgenic mice expressing recombinases under the control of
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Stem Cells. Southern hybridization of ES cell DNA using a 3' 8amHI-Xhol probe
to show 10.5 kb wild type and 6.7kb Ets1~VII (floxed) targeted alleles. Vllfloxed=
Targeted unrecombined allele, G418 r= resistant to the Neomycin analog G418.
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Generation of Ets1AVil Homozygous Mice
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Figure 2.5 Cre Recombination In Vitro by Adenoviral Transduction of
Targeted Embryonic Stem Cells. Flow diagram illustrating the process of
generating recombined homozygotes by adenoviral delivery of ere recombinase.
Ad-ere= adenovirus expressing ere recombinase.
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PCR Verification of Cre-Recombination
Ex III
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peR Analysis to Identify ere-Recombinants
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t.VII (p1+p3)-----+
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P1-'~ +-p2
t.Vllcond (p1+p2)-----+ .
+/+ (p1 +p2)-----+
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Figure 2.6 PCR Verification of Cre Recombination. A. Targeted allele
provides genomic context by illustrating localization of primer pairs (arrows) and
loxP elements (black triangles). B. Schematic depiction of a targeted
heterozygote (left) undergoing Cre mediated recombination (arrow) to form a
Recombined heterozygote (right). C. PCR verification of recombination. 394 bp
Recombinant (~VII), 231 bp Targeted (~Vllcond) and 167 bp Wild type (+/+) alleles
indicated with primer pairs. Heterozygous Targeted (lanes 3, 4 and 6) and
recombined (lanes 2 and 5) cells and Targeting vector (TV, lane 1) control are
shown. Drawings are not to scale. Genotyping was performed by 3 primer PCR
with Amplitaq Gold (Applera Inc, Foster City Ca), 95°C for 10 minutes followed by
36 cycles of 95°C for 1 minute, 64°C for 1 minute and 72°C for 4 minutes.
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were generated by aggregating clonal clumps of approximately 12 ES cells
with pairs of recipient C57BI/6 morulas in a sandwich-type configuration.
Chimeric morulas were cultured in vitro overnight and the resulting expanded
blastocysts were implanted into CD1 pseudo-pregnant foster mothers.
Chimeric males that demonstrated greater than 20 0/0 agouti coat color and
derived from TC1 ES cells were mated weekly with C57BII6 or 129SV
females. Germ line transmission was detectable by agouti coat color in the
progeny of chimeras with C57BII6 females. Generation of Ets1i\Vll cond
heterozygotes was confi rmed by Southern Blot on F 1 offspring from chi mera
matings by the same strategy used to identify targeted ES cell lines. Out of 38
F1 pups, 25 (14 male, 11 female) were identified as targeted heterozygotes
(660/0). Mice verified by Southern blot analysis were subsequently used to
validate a PCR strategy for identifying the targeted allele from genomic DNA.

2.2.5 Generation of Homozygous Mutant Mice
Mice were generated from recombined ES cells by morula aggregation as
described previously (generation of Ets1i\VllflOxed mice). Mice heterozygous
for the Cre-recombined allele were then crossed with either 129SVEvTac
mice for two generations to generate a co-isogenic line of mice or backcrossed onto C57BI/6 for 10 generations to generate C57BI/6 congenic mice.
Heterozygous intercrosses within each strain were used to generate
analyzable mice. Data in this dissertation represents experiments conducted
on the 129SVEvTac background. Ets1i\VII homozygotes are born at less than
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the expected Mendelian ratio from heterozygous intercrosses suggesting a
low penetrant pre- or perinatal lethality on the 129SVEvTac genetic
background (insufficient data for similar determination on C57BI/6
background) (X 2= 8.53719; p<0.015; TABLE II). This lethality ranges from a
trend reduction in female homozygotes (220/0; X2= 2; p=ns; TABLE II middle)
to a 370/0 reduction in male homozygotes (x 2 = 7.05970; p=0.0293; TABLE II
bottom). The exact ti me and cause of lethality have yet to be determi ned, but
preliminary phenotypic analysis of surviving mice has revealed immune and
cardiovascular defects which may contribute to this lethality, and neurological
defects that are less well characterized. Surviving mice mature to adulthood,
are fertile, and are not overtly distinguishable from wild-type littermates based
upon behavioral or physical differences. Body weight is similar between wild
type and homozygotes, with a statistically insignificant trend towards larger
heterozygotes (Fig 2.7)

2.2.6 Verification of Expression
Herein the generation of mice bearing recombined targeted alleles has been
described. However, the generation of a mouse model requires not only that
the desired mutation be introduced into the genome, but also that it gives rise
to the intended gene products. Verification of both transcript and protein
expression of from Ets1 ~ VII mice by was accomplished by reverse
transcriptase PCR (RT-PCR), real-time PCR (qPCR), and Western blot
analysis respectively. Two sets of Ets1 specific primers were used. The Ets1

51

A.

+/+
+NII
VIINII

0.25

73

60.5

2.582645

21%

0.5

127

121

0.297521

5%

0.25

42

60.5

5.657025

-31%

X2=

8.53719

0.014001

p=

B.
Female Genotypic Distribution of Ets1AVil Mice
Genotype

+/+
+NII
VIINII

probability

observed

expected

(o-e)2/e

0.25

31

27

0.5925926

0.5

56

54

0.0740741

0.25

21

27

1.3333333

x2=

(o-e)/e
15%
40/0

-22%
2.00000

p=

0.3678

c.
Male Genotypic Distribution of Ets1AVil Mice
Genotype

+/+
+NII
VIINII

probability

observed

expected

(o-e)2/e

(o-e)/e

0.25

42

33.5

2.1567164

250/0

0.5

71

67

0.238806

60/0

0.25

21

33.5

4.6641791

-370/0

x2=
p=

7.05970

0.0293

Table II. Genotypic Distribution of Ets1AVil Heterozygous Intercrosses.
Non-Mendelian inheritance was noted in heterozygous intercrosses of 129 strain
Ets1 L\ VII mice, with lower than expected numbers of homozygotes suggesting
perinatal or prenatal lethality. A. Total genotypic distribution suggests 30%
lethality (p=0.014) in Ets1 L\ VII homozygotes. B. Trend towards decreased
viability is observed in Female Ets1L\ VII homozygotes (22% reduction, p=ns). C.
More pronounced lethality is observed in Male Ets1 L\ VII homozygotes (37%
reduction, p=0.029).
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Body Weight by Gender and Genotype in 7-21 Week Old
Mice
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Figure 2.7 Body Weight Variance by Genotype in Ets1AVil Mice. Total body
weight of adult 129 strain mice plotted by genotype. Black circles represent
individual mice. Total, female and male means are represented by black box,
white circle and white boxes respectively, ± standard deviation. This distribution
was found not statistically significant by one way ANOVA analysiS.
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full-length specific primer set, which recognizes only full-length Ets1 transcript
but not the Ets 1~ VII transcript, contains a forward primer that binds exon VII
sequence, and a reverse primer that binds exon VIII sequence thereby
eliminating any spurious amplification of genomic DNA. The Ets1LlVil
specific primer set includes one primer that spans the exon VI-VIII junction,
and one primer that binds within exon VI. The intron spanning primer binding
site eliminates the possibility of genomic of full-length transcript amplification.
Loss of the full-length transcript and expression of the Ets1 ~ VII transcript in
flow sorted thymocytes were verified by qPCR (Table III) using the SYBR
green method. Relative transcript levels were calculated by the MCt method,
relative to p-Actin. In 129SvEvTac strain thymocytes Ets1 Ll VII was
determined to be the most abundantly expressed Ets1 isoform transcript in
this analysis. Homozygote expression of the Ets1 Ll VII transcript ranges from
12% reduction to two-fold elevation relative to wild-type mice depending upon
thymocyte subset (Table III). Additionally, the two-fold elevation in Ets1LlVII
transcripts in homozygous CD4-CD8+ cells may be related to these cells
normally expressing the lowest levels of full length Ets1 transcript in Wild-type
mice. Consistent with other published studies the highest expression of all
Ets1 transcripts is in the CD4+CD8+ population of thymocytes in Ets1~VII
homozygotes and Wild-type littermates (Anderson, Hernandez-Hoyos et al.
1999). Such previous studies, however do not distinguish between Ets1
isoforms when measuring Ets1 transcript levels. In an effort to increase the
power of the previous analysis, Ets1 transcript levels were assessed in
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Relative Quantification of Ets1 Transcripts in Wildtype and Targeted Mice
:l

36.71
36.16
37.18
36.45
31.69
31 .36
32.36
31 .67

37.14
36.23
38.19
37.41
31.85
31 .30
32.61
32.02

36.93
36.20
37.69
36.93
31.n
31 .33
32.49
31.85

11.85
9.79
11.91
11 .55
6.70
4.93
6.71
6.07

--

:l

40.00
40.00
40.00
40.00
36.16
31.18
31.06
31.71

40.00
40.00
40.00
40.00
34.63
32.19
30.82
31.28

40.00
40.00
40.00
40.00
35.40
31.69
30.94
31 .50

5.96
5.05
5.70
6.25

-0.74
0.12
-1 .02
0.18

.- .

1.670
0.920
2.028
0.883

Table III. Relative Quantitation of Ets1 Transcripts by qPCR in Ets1AVil
Mice. SYBR-Green real-time PCR on cDNA from FACS purified thymocytes.
ETS1 fuil indicates analysis using a primer set specific to the full-length Ets1
transcript. ETS1 L1VII indicates analysis using a primer set specific to the Ets1~VII
transcript. No full-length transcript was detected in Ets1 ~ VII homozygotes.
Ets1~Vlllevels ranged from 0.9-2.0 wild-type levels depending upon thymocyte
subset. Replicates and means of each genotype shown. ~CT= threshold cycle.
DN= CD4-CD8-, DP= CD4+CD8+, SP4= CD4+CD8-, SP8= CD4-CD8+
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additional mice, from total thymus cDNA and total spleen cDNA by RT-PCR
(Fig 2.8). Identical primer sets to those used in the qPCR analysis were used,
with the exception that HPRT specific primers were used as a control rather
than

~-Actin.

As with the qPCR, loss of full length Ets1 transcript was

observed in homozygotes even at high cycle amplification. Surprisingly
however, the relative levels of full length and ~ VII transcripts were in
disagreement with the previous qPCR analysis. In this analysis, the fulllength transcript predominates in wild type mice in both thymus and spleen,
which is in agreement with previous reports (Barton, Muthusamy et al. 1998).
Even more striking, the levels of the ~ VII transcript show a marked
upregulation in homozygotes relative to wild type mice in both thymus and
spleen. While it is not clear why this discrepancy exists between the two
analyses there are a number of likely explanations. The qPCR analysis was
based upon analysis of highly purified thymocytes, where the RT-PCR
analysis was done on heterogeneous mixtures of cells of the thymus and
spleen, including stroma and other support cells. A second distinction is the
choice of house-keeping gene control, and the comparative analysis of their
fitness for this purpose may be in order for future studies. Lastly, the qPCR
results represent a single mouse, and may be subject to individual variation.
Loss of the full length Ets1 protein and expression of the

Ets1~ VII

protein was

confirmed by Western blot (Fig 2.9). Additionally the western blot
demonstrated that full length Ets1 is the major isoform in wild-type mice. In
mice bearing only a single copy of the ~ VII allele there is a marked
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Verification of Transcript Expression in

Ets1~VII

Mice

A. Strategy for Ets1 Isoform specific PCR

* Recognizes only full-length transcript

B. Verification of Transcript Experssion in Ets1L\VII Mice by RT-PCR
Q)

Q)

16

16

a.

a.
Thymus
+/+

VIINII

Spleen
+/+

VIINII

~

Thymus

s:

+/+

Spleen

VIINII +/+

VIINII

.--~

~

Ets1-FI

Ets1L1VII
HPRT
39 cycles

30 cycles

Figure 2.8 Semi-Quantitative RT -peR Determination of Ets1 Transcript
Expression in Ets1AVil Mice. A. Strategy for Ets1 isoform specific peR. Primer
sets recognizing full-length Ets1 transcript (left) and Ets1~ VII transcript (right) are
shown. Arrows indicating primer 1 (p1) and primer 2 (p2) are shown. Drawing is
not to scale. B. Isoform specific primers were used to measure full-length Ets1
transcript (Ets1-FI) and the alternatively spliced ~VII transcript (Ets1~VII) in total
thymus or spleen cDNA from Ets1 ~ VII mice and littermate controls. HPRT
expression served as a loading control. Expression was measured at 39 cycles
(left) and 30 cycles (right). (-)Template= No template negative control.
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A.
+1+

L1VII/+

L1 VII/L1 VII
Ets 1full

length

Ets1L'lVIl

~-Actin

Spleen

B.
+1+

~

L1VII/+ L1 VIIIL1 VII
Ets 1full

length

~

Ets1L'lVIl

~-Actin

Figure 2.9 Western Blot Confirmation of Protein Expression From the
Ets1AVil Targeted-Recombined Allele in Thymocytes and Splenocytes.
Western blot analysis of total thymus protein (A) and total spleen protein (B)
shows the loss of expression of full-length Ets1 in all homozygote mice. Fulllength Ets1 is the slower migrating band and may appear as a doublet when
phosphorylated as denoted by arrows in B. Continued and increased
expression of Ets1~VII (faster migrating band) is also observed in Ets1~VII
heterozygotes and homozygotes. Beta-Actin loading control is shown.
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upregulation of Ets1AVil protein and concomitant decrease in the level of the
full-length Ets1 protein. This result most likely suggests that relative Ets1
isoform levels are strictly maintained in normal lymphoid tissues via a
feedback auto-regulatory mechanism. In our studies, wild type thymocytes
reproducibly have a lower proportion of the Ets1AVil protein (Fig. 2.9, faster
migrating band). In other studies, this proportion has been reported to be
more variable (Barton, Muthusamy et al. 1998). These protein data are most
are in agreement with the RT-peR data with respect to upregulation of the
AVII expression in homozygotes. Given that these western blots were run with
total organ protein extracts, this may further support the idea that elevated
AVII expression is localized to thymic epithelial cells or other supporting cells
of the thymus.

2.3 Generation of Ets1 s ->A Mice

2.3.1 Design and Construction of a Targeting Vector
The physiological importance of the AVII domain, the functional abilities of this
domain in protein-protein partnering as well as auto-inhibition of DNA binding,
and the generation of mice null for this domain have been described. The
Ets1 AVII mice, totally lacking this domain, will reveal phenotypes associated
with loss of both protein-protein interactions requiring this domain as well as
the loss of responsiveness to phosphorylation mediated repression of Ets1
activity. In order to determine the relative contribution of each of these
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functions to the phenotypes observed in Ets1 ~ VII mice, another line of mice
was designed. The exon VII domain is conserved across species, and is
serine rich (Fig 2.10). As described previously phosphorylation of key serine
residues in the exon VII domain stabilizes the DNA binding inhibited
conformation of Ets1 resulting in up to 1000 fold reduction in Ets1 activity. A
gene targeting strategy was designed to eliminate phosphorylation induced
auto-inhibition of Ets1 by mutation of the necessary serine residues (Fig
2.11). PCR-based site directed mutagenesis was used to convert the key
serine residues 251, 257, 282, and 285 to Alanine. Serine residues 254 and
260 which are clustered with the 251/257 group were also converted to
Alanine. Site directed mutagenesis was confirmed by sequencing. A floxed
Neomycin positive selection cassette was inserted into a Clal site
approximately 2kb 3' to exon VII to generate an isogenic DNA vector with
14kb of homology (Fig 2.11).

2.3.2 Identification of Targeted ES cells
The targeting vector was linearized with Not I restriction endonuclease and
electroporated into TC1-1 0 ES cells, as described previously. Electroporated
cells were cultured on mitotically inactivated mouse embryonic 'feeder'
fibroblasts and treated with G418 for positive selection of cells that have
incorporated the Neo cassette into their genome. Drug-resistant ES cell
clones were expanded and screened for homologous recombination by
Southern blot analysis. As seen in Fig 2.11, the successful integration of the
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organism
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sequence
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Low campi exity

Figure 2.10 The Exon VII Domain is Conserved Across Species. Multiple sequence alignment of exon VII protein sequence
reveals high conservation across chordates. Differences are highlighted in red. Serine residues that participate in phosphorylationmediated autoinhibition of Ets1 are indicated in green. Low complexity sequence is indicated by lowercase grey letters.
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Figure 2.11 Ets1 Genomic Structure and Ets1 s ->A Targeting Strategy. A. Ets1
Genomic structure and restriction map of an Ets1 genomic clone isolated from a
129/Sv mouse genomic library. Restriction sites B= BamHI, Bg= BgllI, C= Clal,
N= Notl, and X= Xhol. 3' Flanking probe and 10.5kb wild type BamHI fragment
are indicated. B. The structure of the Ets1 s->A targeting vector. loxP elements
(black triangles) flank a G418 resistance cassette (neo; white and hatched
rectangle). Exon VII was subcloned with BgllI, and subjected to site directed
mutagenesis (black exon), and reintroduced for co-transfer with the Neo
cassette. C. The structure of the targeted allele. The reduction in size of the 3'
BamHI fragment is indicated.
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Ets1 s->Atargeting vector by homologous recombination results in the inclusion
of an additional BamHI recognition site from the Neo cassette in intron VII of
Ets1. Therefore, BamHI digestion of genomic DNA can be used to distinguish
wild type from targeted alleles by the down shift of the 10.5 kb wild type
BamHI fragment to a 6.2kb fragment in targeted alleles, when hybridized with
a probe from sequence flanking the 3' end of targeting vector homology.
Targeted alleles were detected in 18 of 72 G418 resistant ES cell colonies
(250/0), recognizable by the presence of both 10.5kb and 6.2kb bands (Fig
2.12 A). Because the engineered mutation is only co-transferred with the Neo
selectable marker and the possibility of endogenous mismatch repair genes
reverting the engineered mutation, targeting was further verified by a PCR
based approach using both mutation specific and wild-type primers (Fig 2.12
B and C). Twelve of the 18 ES cell clones (66%) previously confirmed to be
homologous recombinants retained the engineered mutations.

2.3.3 Germ Line Transmission of the Targeted Allele
Targeted ES cells, confirmed by peR and Southern Blot analysis, were used
to generate chimeric mice by ES cell-morula aggregation, as described
previously. Resultant chimeric males that demonstrated greater than 20%
agouti coat color and derived from TC1 ES cells were mated weekly with
C57B1/6, CD1, or 129SV females. Germ line transmission was detectable by
agouti coat color in the progeny of chimeras with C57BI/6 or CD-1 females.
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A.

Southern Blot Analysis of ES cell DNAs
, +-Wildtype
+-Targeted
18 targets/72 G418r clones

M

B.

PCR Primers for Genotype Analysis
238 bp
exon VII

I

II

M6bp-------------------

c.

PCR Verification of Nucleotide change in ES cells
.~.;_.,,~._~_.._~:.;'4-Wildtype

, -

+-MutExVIl
12/18; 66% Co-transfer

Figure 2.12 Confirmation of Ets1 s ->A Gene Targeting. A. Southern blot
analysis of targeted ES cells. BamHI digest of genomic DNA shows 10.5kb
wild type and 6.2kb targeted alleles. M=A-Hind III molecular weight markers.
B. PCR primer design for verification retention of serine to alanine
conversions. White box indicates Exon VII; black rectangles indicate serine to
alanine conversions. One genotyping primer is specific to the mutated
residues. Band sizes indicated. C. Representative PCR results verifying the
presence of the Ets1 S->A allele, wild type and targeted (MutExVII) alleles
indicated.
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Generation of Ets1 S->A heterozygotes was confirmed by Southern Blot on F1
offspring from chimera matings by the same strategy used to identify targeted
ES cell lines. Out of 25 F1 pups, 9 were identified as targeted heterozygotes
(360/0; Fig 2.13 A). Mice verified by Southern blot analysis were subsequently
used to validate a PCR strategy for identifying the targeted allele from
genomic DNA (Fig 2.13 B).

2.3.4 Generation of Homozygous Mutant Mice
Heterozygous offspring from chimera matings were crossed with either
129SVEvTac mice for two generations to generate a co-isogenic line of mice
or back-crossed onto C57BII6 for 10 generations to generate BI6 congenic
mice. Heterozygous intercrosses within each strain were used to generate
analyzable mice. Ets1 S->A mice are born at expected Mendelian ratio from
heterozygous intercrosses suggesting this mutation is less deleterious that
the complete lack of exon VII (X

=2.584906; p<0.28; TABLE IV). Mice mature

2

to aduithood, are fertile, and are not overtly distinguishable from wild-type
littermates based upon behavioral or physical differences. The decreased
lethality relative to that seen with complete exon VII deletion might have been
predicted, based upon the idea that these mice are expected to retain the
protein-protein interaction function of the exon VII domain and thus have only
a subset of the defect represented by deletion of the entire domain.
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A.

Southern Blot Analysis of Tail DNA

Wild Type ......
Targeted ......

9 of 25 (36%) targeted

B.

Genotype Analysis of Tail DNA by peR

Targeted -+

Figure 2.13 Confirmation of Germ Line Transmission of the Ets1 5 ->A Allele
by Southern Blot and PCR. A. Southern hybridization of mouse tail DNA
using a 3' 8amHI-Xhol probe to show 10.5 kbwild type and 6.2kb Ets1 S->A
targeted allele. Wild type and targeted alleles indicated. B. Representative
peR to genotype Ets1 s ->A mice. Wild type and targeted bands are indicated.
Last lane contains <f>X Haelll molecular weight markers.
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Total Genotypic Distribution of Ets1S->A Mice

Genotype
+/+
+/SA
SAlSA

probability

observed

expected

(0-e)2/e

0.25

32

26.5

1.141509

0.5

45

53

1.207547

0.25

29

26.5

0.235849

X2=

2.584906

p=

0.274596

Table IV. Genotypic Distribution of Ets1 s ->A Heterozygous Intercrosses.
Mendelian inheritance was noted in heterozygous intercrosses, with expected
numbers of homozygotes suggesting this does not impart perinatal or prenatal
lethality.
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2.3.5 Verification of Expression
Expression of both transcripts and protein from Ets1 S->A mice was confirmed
by RT-PCR and Western blot analysis respectively. RNA was harvested from
whole thymus or whole spleen and used to generate cDNA from an Ets1 S->A
homozygote and two wild type littermates. RT-PCR verification of Ets1
isoform expression was performed as previously described (Ets1full-length
specific primer set, Ets1 ~ VII specific primer set; HPRT primer set; Fig 2.14).
Both the full-length and

Ets1~VII

transcripts were detected in both thymus

and spleen. Full-length Ets1 transcript exhibited variable expression across
genotypes, with a tendency for reduced expression in the thymus of Ets1 S->A
homozygotes. A marked upregulation of the Ets1 ~VII transcript was observed
in both spleen and thymus. Western blot analysis confirmed that both Ets1
protein isoforms are expressed in Ets1 s->A mice (Fig 2.15). Similar to the
protein expression pattern observed in

Ets1~VII

mice, there is a notable,

though less pronounced, upregulation of the Ets1 ~ VII protein in both the
spleen and thymus of heterozygotes and homozygotes. This may implicate
phosphorylation mediated repression of Ets1 acting on its own promoter in
limiting expression in wild type mice. In contrast to the expression pattern
seen in Ets1 ~ VII mice, Ets1 S->A mice also show a marked upregulation of the
full-length Ets1 protein in the spleen, but not thymus of heterozygotes and
homozygotes. Additionally it is atypical to observe higher expression of Ets1
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Figure 2.14 Semi-Quantitative RT -peR Determination of Ets1 Transcript
Expression in Ets1 s ->A Mice. Isoform specific primers were used to measure
full-length Ets1 transcript (Ets1 FI) and the alternatively spliced f). VII transcript
(Ets1 f). VII) in total thymus or spleen cDNA from 129 strain Ets1 S->A mice and
littermate controls. HPRT expression served as a loading control. Expression
was measured at 30 cycles.
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Western Blot Analysis of Ets1 S~A Mice

Thymus

Spleen

+/+

+/+

SAI+ SAl SA +/+

+/+

SAI+ SAl SA

-68.8 kD

....

-52.5 kD

Ets-1 C-20

¢::::l

-40.0 kD
-52.5 kD

p-actin
-40.0 kD

Figure 2.15 Western Blot Confirmation of Protein Expression From the
Ets1 s->A Targeted Allele in Thymocytes and Splenocytes. Increased
expression of full-length Ets1 (black arrow) was in the spleen of Ets1 S->A
heterozygotes and homozygotes in the spleen but not the thymus. Heterozygotes
and homozygotes have increased expression of Ets1~ VII (open arrow) in both
the thymus and spleen. ~-Actin loading control is shown.
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in the spleen than in the thymus of 129 strain mice, as seen in these mice,
though the significance of this observation is not immediately clear.

2.4 Generation of Ets1 F1 Mice

2.4.1 Design and Construction of a Targeting Vector
The Ets1 ~ VII mice and Ets1 S->A mice collectively represent an allelic series
designed to demonstrate and dissect the necessary functions of the exon VII
coded domain of Ets1. At least conceptually, by the deletion of the entire
domain, mutant phenotypes due to physiological requirements for the
presence ~VII domain can be identified. The Ets1 s->A mice then provide a
means to attribute the relative contribution of phosphate mediated repression
vs. protein-partnering functions of this domain. To more fully understand the
biological significance of this important regulatory domain, it is also important
to understand the physiological requirement for the

Ets1~ VII

protein. To test

this requirement, a targeting strategy to generate mice expressing only the
full-length Ets1 was developed (Fig 2.16). peR-based cloning was used to
generate an exon VI Nil fusion, deleting the entirety of intron VI. A Neo
positive selection cassette (as before) was inserted into a 89111 site
approximately 500bp 3' to exon VII. The construct contains 12.5 Kb of
sequence homology, but also a deletion of approximately 4 kb of genomic
sequence (intron VI) which may limit targeting efficiency.
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The Ets1 FI Targeting Strategy
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Figure 2.16 Ets1 Genomic Structure and Ets1 FL Targeting Strategy. A. Ets1
Genomic structure and restriction map of an Ets1 genomic clone isolated from a
129/Sv mouse genomic library. Restriction sites indicated. 3' Flanking probe and
10.5kb wild type BamHI fragment are indicated. B. The structure of the Ets1 FL
targeting vector. loxP elements (black triangles) flank a G418 resistance cassette
(neo; white and hatched rectangle). Exon VII has been fused to exon VI by peR
based cloning and reintroduced for co-transfer with the Neo cassette. C. The
structure of the targeted allele. The reduction in size of the 3' BamHI fragment is
indicated. D. Targeted allele after ere mediated recombination for removal of the
floxed neomycin resistance cassette.
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2.4.2 Identification of Targeted ES cells
The targeting vector was linearized with Not I restriction endonuclease and
electroporated into TC1-10 ES cells, as described previously. Electroporated
cells were grown in G418-containing media for positive selection of cells that
have incorporated the Neo cassette into their genome. Drug-resistant ES cell
clones were expanded and screened for homologous recombination by
Southern blot analysis. As seen in Fig 12.16, the successful integration of the
Ets1 FI targeting vector by homologous recombination results in the inclusion
of an additional BamHI recognition site from the Neo cassette in intron VII of
Ets1. Therefore, BamHI digestion of genomic DNA can be used to distinguish
wild type from targeted alleles by the down shift of the 10.5 kb wild type
BamHI fragment to a 7.4kb fragment in targeted alleles, when hybridized with
a probe from sequence flanking the 3' end of targeting vector homology.
Targeted alleles were detected in 7 of 46 G418 resistant ES cell colonies
(15.20/0), recognizable by the presence of both 10.5kb and 7.4kb bands (Fig
2.17). Targeted ES cells were used to make one high percentage chimera
(approximately -700/0 by coat color) and 4 low percentage chimeras (- 30%
by coat color). None of these chimeras provided germ-line transmission of the
targeted allele.
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Southern Blot Analysis for Ets1FL Targeted ES cells
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Figure 2.17 Confirmation of Gene Targeting by the Ets1 FL Targeting Vector.
Southern hybridization of ES cells DNA using a 3' BamHI-Xhol probe to show
10.5 kb wild type and 7.4kb Ets1 FL targeted alleles. Targeted alleles were
detected in 7 of 46 G418 resistant ES cell colonies (15.2%).
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Chapter 3: Hematological Disorders in Ets1AVil and Ets1 S->A Mice

75

3.1 Thymomegaly
3.1.1 Organ Morphology
Gross anatomic examination of Ets1~VII mice revealed marked thymomegaly
in homozygotes and moderate thymomegaly in heterozygotes. Mean thymic
weight was 600/0 greater in homozygotes (p=2.99E-09 t-test) and 30% greater
in heterozygotes (p=0.00773 t-test) relative to wild-type littermates (Fig 3.1,
p<0.000001 ANOVA). This difference was not attributable to alterations in
total body mass between genotypes, as homozygotes have 69% higher
thymus: body mass ratio than wild type mice (p=B.21 E-OB t-test) and 44%
higher thumus:body mass ratio than heterozygotes (p=0.001671 t-test)
confirming the thymomegaly is a bona fide phenotype (p<0.000005 ANOVA;
Fig 3.2). By organ weight alone, there appears to be a clear dosage
dependent effect, however this does not persist when organ size is
normalized to total body weight. By comparison, the thymuses of Ets1 S->A
mice do not show an increase in organ size, but instead exhibit a statistically
insignificant trend towards modest reduction in organ size (Fig 3.3).
Thymomegaly in homozygotes was not associated with a histologically
identifiable alteration in thymic structure of cortex, medulla or capsule other
than increased organ size (Fig 3.4). More intense hematoxylin staining in the
medulla on some sections potentially indicates increased numbers of mature
thymocytes (see 3.7), though this differential staining is not consistently
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Thymus Weight by Gender and Genotype in 7-21 week Old Mice
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Figure 3.1 Thymomegaly in Ets1AVil Mice is More Severe in Female Mice.
Thymus mass of 7-21 week old 129 strain mice plotted by genotype and gender.
Black circles represent individual female mice and dashes represent individual
male mice. Total, female and male means are represented by black box, white
circle and white boxes respectively, ± standard deviation.
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Thymus: Body Weight Ratio by Gender and Genotype in 7-21
Week Old Mice
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Figure 3.2 Thymomegaly in Ets1AVil Mice is Independent of Total Body
Mass. Thymus:body mass of 7-21 week old 129 strain mice is plotted by
genotype and gender. Black circles represent individual female mice and dashes
represent individual male mice. Total, female and male means are represented
by black box, white circle and white boxes respectively, ± standard deviation.
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Bs1S->AThymus Weigtt by Genotype
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Figure 3.3 No Significant Change in Thymus Size of Ets1 s->A Homozygotes.
Thymus mass of adult mice is plotted by genotype. Black circles indicate individuals;
Black Square indicates mean value of group with 95% confidence intervals indicated by
error bars. This distribution was found not to be statistically significant by ANOVA.
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40x

200x

40x

Figure 3.4 Thymomegaly and Hyposplenia in Ets1AVil Mice is Not
Associated With Overt Structural Changes. Histological analysis of normal
and Ets1 ~ VII thymus and spleen did not reveal significant differences between
genotypes. H&E staining reveals normal architecture of thymus and spleen of
Ets1~VII homozygotes. A. Wild type thymus 40x magnification B. Ets18VII
homozygous mutant thymus 40x magnification C. Wild type thymus 200x
magnification D. Ets18VII homozygous mutant thymus 200x magnification E.
Wild type spleen 40x magnification F. Ets18VII homozygous mutant thymus 40x
magnification. All sections are 7uM, C=cortex, M=Medulla, WP= white pulp,
RP=red pulp.
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observed. Histological examination of Ets1 s->A t hymuses has not been
performed.

3.1.2 Cell Type Distribution
Flow cytometric analysis of isolated thymocytes revealed no statistically
significant differences in representation of thymocyte subsets in Ets 1AVII
mice, though a trend towards increased relative frequency of CD4-CD8+ cells
(2SO/o increase) was observed, (p<O.OSS, Fig3.S-6). To normalize these data
for the number of cells present we multiplied organ weight by relative
frequency of each cell type to determine the calculated cell mass for each
population. This revealed a trend towards increased mean calculated cell
mass in all thymocyte subtypes with 4S o/0 increase in CD4+CD8+ cells and

86% increase in CD4-CD8+ cells achieving statistical significance (p<O.OS, Fig
3.S-6). Consistent with Ets1 isotype disruption, the CD4-CD8+ compartment
showed both the greatest increase in mean calculated mass and the highest
relative increase in Ets1AVil transcripts as measured by qPCR of flow sorted
thymocytes. This thymomegaly is in contrast to the 6S o/0 reduction in thymic
cellularity reported in Ets1 null animals (Barton, Muthusamy et al. 1998),
suggesting that Ets1 AVII may effectively represent transgenic Ets1 activity in
the thymus despite the disruption of the full-length isoform. This would be
consistent with the increased expression of Ets1 transcripts (RT-PCR) and
protein as well as loss of the autoinhibitory Exon VII domain. Moreover
provirus integration into the S' cis-regulatory region of the Ets1 gene has been
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Figure 3.5 Loss of Full-length Ets1 Alters Thymocyte Development. A. Table
of average relative percentages of CD4 and CD8 thymocyte populations in 8-16
week old Ets1 ~ VII targeted mice and wild type littermates. B. Mean calculated
cell mass for each population, calculated as the product of mean relative
percentage of thymocyte population and thymus weight. Relative increase or
decrease of mean Ets1 ~ VII values compared to wild type values are indicated at
the bottom of the chart. DN= CD4-CD8-, DP= CD4+CD8+, SP4= CD4+CD8-,
SP8= CD4-CD8+; 0'= standard deviation, n= number of individual mice assayed
for each genotype. C. Dot plots of CD4/CD8 double labeled thymocytes from
Ets1 ~ VII and wild type mice. Relative percentages indicated in each quadrant.
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Relative Percentage of coa+CD4- Thymoctyes
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Figure 3.6 Statistically Significant Alterations in Thymocyte Cell Type
Distributions in Ets1AVil Mice. A. Relative increases in CD8+ thymocytes B.
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shown to induce thymic lymphoma coincident with an increase in Ets1
expression (Bellacosa, Datta et al. 1994). Alternately the possibility exists that
full-length Ets1 acts as a repressor in the thymus via phosphorylation of the
Exon VII domain (Liu and Grundstrom 2002; Dittmer 2003).

3.1.3 Mechanistic Basis
In order to establish the etiology of the thymomegaly in Ets1L\VII mice we
assessed cell proliferation, apoptosis, and cell size. No significant differences
in cell size were detected by comparison of mean forward scatter (FSC) of
freshly isolated thymocytes irrespective of genotype.

3.1.3.1 Proliferation
To determine the role of cell proliferation in the thymomegaly of Ets1L\VII
mice, mice were administered 5-bromodeoxyuridine (BrdU) IP and S-phase
cells were measured by IHC. In contrast to reports of Ets1 null mice having
normal cell cycle for unchallenged thymocytes and splenocytes (Bories,
Willerford et al. 1995; Muthusamy, Barton et al. 1995), Ets1L\VII homozygotes
showed a marked increase in the number of proliferative cells of both the
spleen and thymus relative to wild type littermates. In the wild type thymus,
the vast majority of proliferating cells are found in the subcapsular region, with
more diffuse BrdU staining in the cortex, and few proliferating cells are
detected in the medulla. By contrast thymuses of Ets1L\VII homozygotes
contain a marked increase in the levels of proliferating cortical thymocytes, to
levels comparable to the subcapsular region (Fig 3.7). The zone of
proliferating cells in the subcapsular region of homozygotes appears less
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40x

Figure 3.7 Increased Proliferation in the Cortex of Ets1AVil Thymus by BrdU
IHC. BrdU staining of 7uM thymus sections from wild type (A) and Ets1AVil
homozygotes (B) demonstrates increased proliferation in the cortex of
homozygote thymuses. SC= subcapsular, C= cortex, M= medulla; 40x
magnification.
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organized and less distinct than seen in wild type mice. This altered
distribution may result from a loss of regional specificity of subcapsular CD4CD8- or CD4 +CD8+ thymocytes and/or increased proliferation of thymocytes
normally found in the cortex. Though our data did not achieve statistical
significance, the trend towards increased relative proportion of CD4-CD8cells (relative to CD4+CD8+ cells) suggests the former. Given that the highest
concentration of CD4-CD8- cells is normally thought to be in the subcapsular
zone of the thymus while the vast majority of cortical thymocytes are
CD4+CD8+, the model supporting generalized cortical thymocyte proliferation
would predict increased CD4+CD8+ cell representation, while the loss of
regional specificity model would allow for increased representation of CD4CD8- cells. This however is a matter of speculation, and available data do not
allow for a definitive answer. BrdU incorporation may be regarded as the gold
standard for determining proliferative index by immunohistochemical means
(Zacchetti, van Garderen et al. 2003), however, it offers the disadvantages
that it may be metabolized or incorporated during DNA repair. Proliferation
observed by BrdU labeling, was confirmed by immunohistochemical
evaluation of proliferating cell nuclear antigen (PCNA) (Fig 3.8). PCNA
staining revealed marked increase in the proliferation of cortical thymocytes of
Ets1~VII

mice. This is consistent with BrdU labeling, though the subcapsular

zone of proliferation was not as pronounced as seen in the BrdU labeled wild-
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Figure 3.8 Increased Proliferation in Ets1AVil Thymus by PCNA IHC. PCNA
staining of 7uM thymus sections of wild type thymus (A and E; 40x and 200x
respectively) reveals increased proliferation in Ets18VII thymus (C and G; 40x
and 200x respectively). Serial sections not treated with PCNA antibody served as
negative controls, pictured for wild type 40x (B), Ets18VII homozygote 40x (0),
wild type 200x (F), Ets18VII homozygote (H). Cap= Thymic capsule, C= co rte[< ,
M= medulla
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type mice. These data collectively implicate increased cortical thymocyte
proliferation (CD4-CD8- and CD4+CD8+ populations) as a contributing factor
for thymomegaly.

3.1.3.2 Apoptosis
Ets1 has an established role in apoptosis, and ectopic expression of the
Ets1 ~ VII isoform but not the full length isoform restores Fas mediated
apoptosis in DLD-1 cells and MDA-MB-231 breast cancer cells (Li, Pei et al.
1999; Ballschmieter, Braig et al. 2003). To determine the contribution of
apoptosis to the thymomegaly

Ets1~VII

mice, primary thymocytes were

stained with annexin V and subjected to flow cytometric quantification.
Annexin V detects the early membrane asymmetry of phosphatidylserine
characteristic of cells initiating apoptosis. Consistent with the observed
thymomegaly, total thymocytes of both Ets1 ~VII homozygotes and
heterozygotes had a 50% mean reduction in the frequency of apoptosis,
compared to wild-type littermates (p<0.001, Fig 3.9-10). This is in contrast to
the diminished survival reported in Ets1 null (neomorph) mice and
complemented Rag2-1- chimeras (Muthusamy, Barton et al. 1995; Eyquem,
Chemin et al. 2004). These results suggest that the relative dosage of Ets1
isoforms may be a critical modulator of apoptosis, as Ets1 AVII/+ mice exhibit
intermediate effect. Alternatively there may be a threshold of either Ets1
isoform above (Ets1~VII) or below (full-length Ets1) which apoptosis is not
efficiently induced, though as noted above reports on loss of Ets1 expression
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Figure 3.9 Marked Reduction in the Apoptotic Rate of Ets1AVil
Thymocytes. A. Merged histogram demonstrating diminished apoptosis in
Ets1 ~ VII thymocytes relative to wild type littermates. Representative histograms
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with percentages of apoptotic cells indicated.
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Annexin V Positive Thymocytes by
Genotype
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Figure 3.10 Variance of Annexin V Staining in Ets1AVil Thymocytes.
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value of group with 95% confidence intervals indicated by error bars.
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argue against the latter. Cell survival is a key regulatory mechanism of
thymopoiesis, allowing the elimination of defective or inappropriate
thymocytes. Abnormal increases in thymocyte survival may lead to either
immune deficiency by maintenance of defective T cells or to autoimmunity by
the maintenance of self-reactive T cells. Underscoring this point, less than

50/0 of all thymocytes survive this process to become mature T cells (Lucas,
Vasseur et al. 1993). It is unclear which of these steps are affected by
increased expression of Ets16.VII and/or loss of full-length Ets1. Thus we
have demonstrated an increase in thymus size that can not be attributed to a
single subset of thymocytes, thus implicating the earliest developmental stage
assayed, namely CD4-CDS-. We further showed both increased proliferation
of thymocytes and diminished apoptosis in these cells. Collectively this data
suggests that negative selection of thymocytes is defective or inefficient and
that positive selection may allow expansion of thymocytes that are incapable
of binding self-MHC. A demonstrated role for Ets1 in

~-selection

has

previously been reported in Ets1 null mice (Eyquem, Chemin et al. 2004;
Clements, John et al. 2006). Herein we have provided data suggestive that

~

selection is also defective in Ets16.VII mice. It is also interesting to note that
the trend towards increased representation of CD4-CDS+ thymocytes
observed in our mice contrasts with the recently reported impaired generation
of CD4-CDS+ thymocytes in Ets1 null mice (Eyquem, Chemin et al. 2004;
Clements, John et al. 2006).
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3.1.4 Molecular Basis
3.1.4.1 Molecular basis for proliferation
To investigate the molecular mechanism underlying the increased
proliferation in Ets1 ~VII thymuses, we looked for alterations in the expression
of Cdkn2a (altemately named p161NK4a) and Cdkn1b (alternately named
p27KiP1 ). There are a number of reasons for further investigation of these
genes. These two proteins are reported to be expressed throughout the
thymus, at levels consistent with roles as important regulators of thymocyte
proliferation in normal adult mice (Kanavaros, Stefanaki et al. 2001)
Furthermore, alterations in the expression of these proteins have been shown
to be important in lymphoid organ size. Transgenic mice that overexpress
either Cdkn2a or Cdkn1 b show partial developmental arrest at the CD4-CD8stage, reduced proliferation and function of lymphocytes (Tsukiyama, Ishida
et al. 2001) (Lagresle, Gardie et al. 2002). Gene targeted mice deficient in
either Cdkn2a or Cdkn1 b develop thymic hyperplasia (Nakayama, Ishida et
al. 1996) (Fero, Rivkin et al. 1996) (Sharpless, Bardeesy et al. 2001). Mice
deficient in Cdkn1 b also develop splenic hyperplasia. In our studies, western
blot analysis of total thymocytes from Ets1 ~VII homozygotes and
heterozygotes show decreased expression of Cdkn2a relative to wild type
littermates (Fig 3.11 A). As mentioned above, this is consistent with reported
data that reduced expression of either gene results in hyperplasia. Ets1 is a
known activator of Cdkn2a transcription, though the relative contribution of
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Decreased Expression of Cyclin-Dependent Kinase Inhibitor 2A Protein in the
Thumuses of Ets1AVil Heterozygotes and Homozygotes

A.

+/+
~VII/~VII
~VII/+ - - - - - - ~VI 1/+ - - - - - -

Cdkn2a
B-Actin

B.
+/+

VIINII

SAlSA

Cdkn2a
HPRT
30 Cycles

Figure 3.11 Reduced Expression of Cdkn2a Protein in Ets1AVil Thymus.
A. Western blot analysis of total protein from isolated thymocy;es shows
diminished expression of CDKN2a (alternately named p16 1NK a) protein in
Ets 1~ VII homozygote (~VIII~ VII) and heterozygote (~VII/+) thymocytes relative
to wild type (+1+) thymocytes, ~-actin loading control. B. Reduction in Cdkn2a
transcripts in Ets1~VII homozygotes (VIINII) but not Ets1 s ->A homozygotes
(SAlSA) by RT-PCR analysis of total thymus eDNA, HPRT loading control.
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each Ets1 isoform in this process has not been reported (Ohtani, Zebedee et
al. 2001; Huot, Rowe et al. 2002). To examine the possibility that reduced
Cdkn2a protein expression may be directly mediated by isoform-specific
alterations in Ets1 transcriptional activity, Cdkn2a transcript levels were
measured by RT-PCR on cDNA from total thymus extracts (Fig 3.11 B).
Ets1~ VII

homozygote thymuses have reduced expression of Cdkn2a

transcripts relative to wild-type. Interestingly, Ets1 s->A t hymuses show
elevated Cdkn2a transcript levels. Mechanistically this suggests that exon VII
mediated inhibition of Ets1 transcriptional activity may normally limit
expression of Cdkn2a in the thymus. Additionally, protein partnering at
juxtaposed Ets1-Runx1 or Ets1-Hif2u sites (GenBank AF022809) may
circumvent this repression. Reduction of Cdkn1 b protein expression was also
observed in both the thymus and spleen of homozygotes and heterozygotes
relative to wild-type littermates (Fig 3.12). Real-time PCR measurement of
Cdkn1 b expression in flow sorted thymocyte subpopulations revealed no
alteration in transcript levels between wild type and Ets1 ~ VII homozygotes.
This result suggests that in the thymus Cdkn1 b is not transcriptionally
regulated by Ets1 in an isoform specific manner (Fig 3.13 A) However, an
approximately 50 0/0 reduction in Cdkn1 b transcript levels was detected by RTPCR of cDNA from total thymus RNA, arguing that isoform specific
transcriptional regulation of Cdkn1 b may occur (Fig 3.13 B and C). The
reason for the discrepancy between analyses is unclear and may relate to the
distinction between whole thymus vs. sorted thymocytes, or limiting amounts

94

Thymus
+/+

~VIIl+

~VII/~VII

CDKN1b

~-Actin

Figure 3.12 Reduced Expression of Cdkn1b Protein in Ets1AVil
Thymocytes. Western blot analysis of total protein from isolated thymocytes
shows diminished expression of CDKN1 b protein in Ets1 ~ VII thymocytes, ~-actin
loading control.
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Figure 3.13 Cdkn1b Expression Analysis by qPCR and RT-PCR. A. SYBRGreen real-time PCR on cDNA from FACS purified thymocytes reveals increased
or unchanged expression of Cdkn1 b transcript. Replicates and means of each
genotype shown. ~CT= threshold cycle. DN= CD4-CD8-, DP= CD4+CD8+, SP4=
CD4+CD8-, SP8= CD4-CD8+; ~-Actin control. B. RT-PCR analysis of Cdkn1b on
total thymus cDNA reveals a modest reduction in the expression of Cdkn1 b in the
thymus of Ets1~11 homozygotes (VIINII), HPRT control shown. C. Densitometric
quantitation of relative Cdkn1 b transcript expression of RT-PCR results shown in
B, values represent means of each pair.
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of RNA in sorted thymocytes. A further confounding variable is the use of
different house keeping genes for RT-PCR and qPCR to normalize transcript
expression values. Though p-Actin and HPRT used in these experiments are
commonly used for such normalization, context dependent variability in
expression of these and other house keeping genes has been reported (Foss,
Baarsch et al. 1998; Moe, Ziliang et al. 2001; Bas, Forsberg et al. 2004). No
alterations in the expression of Cdkn1 b transcripts were observed in Ets1 S->A
mice by RT-PCR (Fig 3.14). This would suggest that either Ets1 is not a direct
transcriptional regulator of Cdkn1 b or that full-length Ets1 augmented
transcription is required for normal expression of the Cdkn1 b gene.
Collectively the results observed in Ets1L\VII and Ets1 s->A mice suggest the
latter through a mechanism dependent upon protein partnering synergies
rather than escape from phosphorylation mediated inhibition. In summary we
observe reduced expression of the cell cycle inhibitor proteins Cdkn2a and
Cdkn1b in the thymus of Ets1L\VII mice, and similar reduction of transcripts by
RT-PCR (but not qPCR of sorted thymocytes) in these mice. RT-PCR
analysis of Ets 1S->A thymuses demonstrates no alteration in the levels of
Cdkn1 b transcripts in the thymus but increased expression of Cdkn2a
transcripts. Taken together our results support the idea that normal
expression of Cdkn2a and Cdkn1 b may require transcriptional activation by
full-length Ets1 and in Ets1L\VII mice the absence of this isoform in
homozygotes (or diminished expression coupled with competitive inhibition of
full-length Ets1 DNA binding by increased levels of Ets1L\VII protein in
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Figure 3.14 No Change in Expression of Cdkn1b Transcripts in Ets1 s ->A
Thymus. RT -peR analysis of total thymus cDNA from 129 strain Ets1 S->A mice
shows no change in transcript expression in Ets1 S->A homozygotes (SAlSA)
relative to wild type littermates (+/+). HPRT loading control is shown, 30 cycles.
(-) Template= no template negative control lane.
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heterozygotes) reduced expression of Cdkn2a and Cdkn1 b leads to
increased thymocyte proliferation. Furthermore these results suggest that
phosphorylation-mediated inhibition of Ets1 activity may normally limit
expression of Cdkn1 b transcripts, but not Cdkn2a transcripts. Other genes
involved in thymocyte proliferation and genes directly regulating apoptosis
have not yet been studied in these mice.

3.1.4.2 Molecular Basis for Functional Compensation
One challenge to using reverse genetic approaches to identify gene function
is that animal models sometimes present with minimal or complex
phenotypes as a consequence of functional compensation to the engineered
mutation. Likely mediators of such compensation might include paralogs of
the targeted gene which may retain sufficient homology to act as surrogates
(e.g. redundancy with other ETS family members with Ets1), or modifier
genes that are known to have functional interactions with the targeted gene,
or genes that have demonstrated functions related to phenotypes observed in
gene targeted animals (e.g. downstream target genes of a transcription
factor). Runx transcription factors are implicated as potential compensatory
genes to Ets1 by ontogeny, functional interactions with Ets1, overlapping
expression pattern, and phenotypic similarities to Ets1 mutant animals. Runx
genes are important regulators of development throughout metazoa, with
demonstrated roles in the differentiation of thymocytes, osteoblasts,
hematopoietic stem cells, and neurons (Okuda, van Deursen et al. 1996;
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Otto, Thornell et al. 1997; Levanon, Bettoun et al. 2002; Taniuchi, Osato et al.
2002). Runx1 has been shown to be a critical regulator of definitive
hematopoiesis in fetal mice, a repressor of CD4 expression, activator of CD8
expression, and is important for

~-selection

(Okuda, van Deursen et al. 1996;

Taniuchi, Osato et al. 2002; Kawazu, Asai et al. 2005). Furthermore, loss of
Runx1 causes splenomegaly in adult mice (Putz, Rosner et al. 2005).

Most

importantly a growing body of evidence supports the role of Runx1-Ets1
activity as a bipartite transcription factor on regulatory elements with
juxtaposed Ets 1 Runx1 consensus recognition sequences through direct
interaction of the exon VII coded domain of Ets1 with the Negative Regulator
of DNA Binding (NRDB) domain of RUNX1 (Wotton, Ghysdael et al. 1994;
Sun, Graves et al. 1995; Kim, Sieweke et al. 1999; Goetz, Gu et al. 2000;
Garvie, Pufall et al. 2002). Similar to the thymic phenotype we observed in
Ets1~VII mice, Runx1 expression is critical for the CD4-CD8- to CD4+CDS+

thymocyte transition and repression of CD4 in thymocyte maturation by a
mechanism requiring its NRDB domain (Kawazu, Asai et al. 2005). Thus our
results and the published results suggest that this phenotype may require
Ets1. To further support this notion, Ets1 may not only partner with Runx1, but
also may regulate Runx1 expression. Ets binding site palindromes, potentially
allowing for synergistic Ets1 homotypic interactions, are found in both
proximal and distal promoters of Runx1 (GenBank #U39636, #U39637).
Real-time PCR analysis of Runx1 expression in flow sorted thymocytes
revealed that Runx1 is Significantly upregulated in CD4-CD8+ and CD4-CDS-
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subpopulations of Ets1~ VII mice at levels of 3.4x and 2.3x wild-type levels
respectively (Fig 3.15 A). This mirrors the upregulation of the Ets1 ~ VII
transcript expression in homozygotes where CD4-CD8+ and CD4-CD8- cells
have 2x and 1.6x wild-type levels of Ets1 ~ VII transcript expression by qPCR,
respectively and further supported by RT-PCR which shows a marked
upregulation of

Ets1~ VII

transcripts in total thymus. However, levels of

Runx1 transcripts in CD4+CD8+ cells were unchanged and reduced
approximately 100/0 in CD4 +CD8- cells, and unchanged in RT-PCR analysis of
total thymus (Fig 3.15 B). Never the less, the increased Runx1 (and
Ets1~VII) transcript expression in CD4-CD8+ and CD4-CD8- cells was also

observed as an increase in protein expression in western blot analysis of total
thymocyte protein extracts. Actin normalized protein expression of Runx1 in
homozygotes ranged from 2.4 to 9 fold higher than the average level of
expression in wild type mice (Fig 3.16). Expression of Runx1 protein in
Ets1~VIII+thymus was comparable to that of homozygotes. In addition to

alterations in expression levels of Runx1, the expression of alternate splice
forms was also detected. Using an RT-PCR primer set which spans an intron
5' to the NRDB (the domain that physically interacts with Ets1 exon VII to
allow protein partnering) of RUNX1 an alternate transcript was detected in
Ets1 ~ VII thymocytes (Fig 3.17). An insertion of equal size was found in
GenBank for human, rat and mouse Runx1 transcripts (GenBank: D10570,
NM_017325 and D13802 respectively), with 96% or greater nucleotide
identity between species in the coding sequence of this alternate exon.
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Figure 3.15 Runx1 Expression Analysis by qPCR and RT-PCR. A. SYBRGreen real-time PCR on cDNA from FACS purified thymocytes using Runx1
primer set reveals variable expression of Runx1 by cell type. Replicates and
means of each genotype shown. ~CT= threshold cycle. DN= CD4-CD8-, DP=
CD4+CD8+, SP4= CD4+CD8-, SP8= CD4-CD8+; ~-actin control. B. RT-PCR
analysis of Runx1 on total thymus cDNA reveals no alteration in the expression
of Runx1 in the thymus of Ets1~VII homozygotes (VIINII) or Ets1 s->A
homozygotes (SAlSA) relative to wild type mice (+/+). The same Runx1 primer
set was used for both methods. HPRT loading control and (-)Template= no
template negative control are shown.
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Figure 3.16 Increased Runx1 Protein Expression in Ets1AVil Thymus. A.
Western blot analysis of total thymus protein extracts from 129 strain mice. Wild
type (+/+), heterozygote (~VII/+) and homozygotes (~VII/~VII) are shown. B.
Densitometry measured ~-Actin normalized expression. Densitometry was
measured using Scion Image Gel Plot.
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Alternative splicing of RUNX1 Transcript in Thymocytes of Ets1AVil Mice
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Figure 3.17 Alternative Runx1 Transcript Expression in Ets1AVil
Thymocytes. A minor splice variant of Runx1 (503 bp amplicon) is detected in
DP (CDS+CD4+) and CDS (CDS+CD4-) but not DN (CDS-CD4-) or CD4 (CDSCD4 +) thymocytes of Ets 11J.VII mice, but is not co-expressed with the major splice
form (310 bp amplicon). (-)Template (no template) negative control and HPRT
loading controls are shown.
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Confirmation that this alternate exon is expressed preferentially in the thymus
of

Ets1~VII

mice will require cloning and sequencing. Its tempting to

speculate that this may represent a RUNX1 adaptation to loss of Ets1 exon
VII mediated synergy. For instance, it is possible that given the limited
homology between Ets2 and exon VII of Ets1 (Fig 3.18) it or some other
protein may compensate for Ets1 on coordinated RUNX1/Ets1 binding sites in
the absence of full-length Ets1.

The extent to which altered expression of RUNX1 can compensate for the
loss of full-length Ets1 activity or the overexpression of Ets1 ~VII as well as
the contribution of Runx1 over expression to the mutant phenotype are not
clear. Thus it is likely that this splice form is a true splice variant and not a
PCR artifact. It is tempting to speculate that this alternate splice form
represents RUNX1 adaptation to loss of Ets1 exon VII mediated synergy or
increased expression of the Ets1 ~VII form. For instance, it is possible that
given the limited homology ( >500/0 identity;

~o%

similarity across chordates

analyzed) between Ets2 and exon VII of Ets1 (Fig 1.1 boxes 56 and 59; Fig
3.18), it or some other protein may compensate for Ets1 on coordinated
RUNXIEts binding sites in the absence of full-length Ets1. Alternatively, it is
possible that such an interaction with Ets2 or other EBS binding protein
serves to inhibit transcription and thereby competitively inhibit transcription
from the highly expressed Ets1 ~VII isoform. Proof of such speculation,
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Figure 3.18 Sequence Homology Between Ets2 and Ets1 Exon VII. A. Pairwise analysis of Ets1 exon VII sequence and Ets2 sequence for multiple species.
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(dark gray), as measured by the number of sequences having identical or simi lar
residues at each respective position.
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however, will require further study. RT-PCR analysis of total thymus cDNA did
not reveal significant alterations in transcript levels of Ets1 S->A or Ets1 ~VII
mice (Fig 3.15). Thus it is not clear what role, if any, phosphorylation
mediated inhibition of Ets1 plays in Runx1 transcript expression.

To determine the capacity of increased Runx1 expression to compensate for
loss of Runx1/Ets1 synergy in

Ets1~VII

mice we measured transcript levels of

known and putative target genes of coordinated Runx1/Ets1 transcription.
Csf2 (alternately known as granulocyte-macrophage colony-stimulating
factor) is a well documented target of Runx1/Ets1 synergistic transcription,
with Ca2 + mediated phosphorylation repressing activity of Ets1 as well as
Runx1/Ets1 coordinate activity (Kim, Sieweke et al. 1999; Liu and Grundstrom
2002; Liu, Holm et al. 2004). Ceteris paribus, loss of exon VII would be
expected to result in a dramatic reduction in Csf2 transcript expression due to
the loss of Runx1/Ets1 synergy, but this reduction would be tempered by
concomitant loss of phosphorylation mediated inhibition of Ets1. Given that
full-length Ets1 protein is much more highly expressed than the ~ VII form in
spleen and thymus of wild-type mice, that Runx1 is co-expressed in these
tissues, and that Ca 2+ flux is tightly controlled under normal conditions, it is
likely that the tempering effect of escape from auto-inhibition provided by the
~ VII

form exerts only minor influence over Csf2 transcript levels. Therefore

we expected a marked reduction of Csf2 transcript in ~ VII homozygotes
relative to wild-type, and a modest increase in Csf2 transcripts in Ets1 S->A
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homozygous mice relative to wild-type if increased Runx1 expression is not
compensatory for the loss of Runx1/Ets1 synergy. This predicted pattern of
expression was indeed observed by RT-PCR of total thymus cDNA (Fig 3.19).
This result demonstrates that increased expression of Runx1 protein in the
thymus of Ets1 ~ VII homozygotes is not sufficient to compensate for the loss
of Ets1/Runx1 cooperativity in these mice. Similar analysis in the spleen,
however, indicated a statistically significant increase in Csf2 expression in
Ets1 S->A homozygotes, with only a modest decrease in expression in the ~ VII
homozygotes relative to wild-type mice (Fig. 3.19). This assessment of Ets1
protein expression, however, relies on the assumption that these samples
represent comparable loads of protein because the J3-actin loading control is
overexposed precluding its use in sample normalization. Since splenic
expression of Runx1 protein was not assessed, it is not possible to relate
splenic Csf2 expression to Runx1 protein functional compensation. However
these results do suggest the possibility that such compensation does in fact
occur. It should be noted that while transcript analysis by RT-PCR in the
spleen was performed, and did not reveal alterations in Runx1 transcript
levels, our results in the thymus suggest that increases in Runx1 protein in
Ets1 ~VII thymocytes was due at least in part to post transcriptional regulation
of expression. Aside from increased Runx1 compensation (e.g. higher
expression of Runx1 in spleen relative to the thymus), other explanations of
this expression pattern may include contextual differences between splenic
and thymic environments. For instance, in the thymus RUNX1 is the
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Figure 3.19 RT -PCR Analysis of Csf2 Expression in Ets1AVil and Ets1 s ->A
mice. A. Total thymus cDNA from 129 strain Ets1~VII (VIINII) homozygotes or
Ets1 s->A homozygotes (SAlSA) relative to wild type mice (+/+) measured by RTPCR using Csf2 primer set, and HPRT control loading control. No Template
negative control also shown. Similar analysis in spleen is shown (right) to
indicate potential tissue specific differences in the expression or Runx1/Ets1
coordinately regulated genes. B. Densitometry measurements of the RT -PCR
shown in (A). Means of net intensity readings (calculated using Kodak Gel Image
software) with statistical significance determined by pair-wise T-Test indicated.
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murine CD44 gene, which has three RUNX1/ETS1 binding sites, was
selected as a promising candidate for subsequent validation for several
reasons (Fig 3.20). CD44 has a well established role in T cell development
and function. In the thymus CD44 is important for homing of thymic
progenitors from the bone marrow to the thymus, and also serves as a
definitive differentiation antigen of subtypes of CD4-CD8- cells (Wu, Kincade
et al. 1993). Studies using antibodies to block CD44 function have
demonstrated a role in lymphocyte activation, differentiation,
homing/migration, and proliferation (Lesley, Hyman et al. 1993; Rafi,
Nagarkatti et al. 1997; Foger, Marhaba et al. 2000; Hogerkorp, Bilke et al.
2003; Ponta, Sherman et al. 2003). Our own data also supports a possible
role for CD44 in the mutant phenotype of Ets1AVil mice. One of the key
functions of CD44 is the homing of thymic progenitors to the cortico-medullary
junction of the thymus, and continues to be required in DN thymocytes in their
differentiation. This process takes the immature thymocytes to the
subcapsular region, whereupon they lose CD44 expression. Our BrdU IHC
data suggests this region is disorganized in Ets1 AVII homozygotes, and
suggests the possibility that diminished CD44 expression may lead to ectopic
localization of these cells throughout the cortex. Furthermore, CD44 has
been shown to affect cell proliferation via post-translational control of Cdkn1 b
expression, and thus could contribute to the diminished expression of Cdkn1 b
protein we observed in Ets1AVil heterozygotes and homozygotes (Gadhoum,
Leibovitch et al. 2004). Taken together, these published data and our own
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Figure 3.20 CD44 Is Potentially Regulated by Coordinate Ets1 RUNX1 Interaction. Analysis of the murine CD44
promoter sequence (GenBank # AF262063) reveals three putative RUNX1/Ets1 coordinated binding sites. indicated by
boxes. Transcription factor binding sites yo/ere mapped using GCG software (Accelerys). ATG represents beginning of
CD44 coding region .

data argued that CD44 is a likely target for Runx1/Ets1 transcriptional
regulation. Accordingly, analysis of CD44 expression in Ets1 ~VII mice was
performed to allow extension of our Csf2 data, which already suggested that
increased expression of Runx1 does not compensate for loss of Runx1/Ets1
synergy. Flow cytometric analysis of CD44 expression in thymocytes of
Ets1~VII

mice demonstrated a reduced frequency of CD44 expressing cells

(Fig 3.21-22). Specifically, the frequency of CD44+ thymocytes (reduced
number of CD44+ ce1ls/1 04 thymocytes) in heterozygotes is comparable to the
frequency in wild-types, but the frequency in homozygotes is reduced by
approximately 40%. Since this assay relies on detection of CD44 expressed
on the cell surface, the possibility remained that post-transcriptional regulation
could account for the decreased CD44 expression. To determine if this
misexpression is due to transcriptional misregulation, as would be predicted
from the RUNX1/Ets1 coordination model, CD44 expression was assessed by
RT-PCR on cDNA from total thymus extract. The primer set used for this
analysis was comprised of intron spanning primers on the 3' end of the CD44
transcript. A clear loss or marked reduction of CD44 transcript was observed
in both of the

Ets1~ VII

mice tested, from total thymus cDNA, relative to wild-

type littermates (Fig 3.23). Given that cell surface expression of CD44 was
detected in thymus our transcript analysis likely indicates that CD44
transcription is markedly reduced but not ablated, and may further suggest
that this altered expression extends to a shift in the abundance of alternatively
spliced transcripts of CD44. This expression of CD44 was unaffected
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D·
7.49%

VII/+

VIINII

Figure 3.21 No Alteration in CD44 Cell Surface Expression on Ets1AVII
Thymocytes. Representative flow cytometry histograms of CD44 expression on
thymocytes are shown. A. Merged histogram of CD44 expression. Green= wild
type, blue= heterozygote, red= homozygote. B, C, D Illustrate representative flow
cytometric histograms for wild types (+/+), heterozygotes (~VII/+) and
homozygotes (~VII/~ VII) respectively with percentages of CD44 expressing cells
indicated.
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CD44+ Thymocytes by Genotype .
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Figure 3.22 Variance in Thymocyte Cell Surface CD44 Expression by
Genotype. Summary of flow cytometric measurement of CD44 cell surface
expression on thymocytes indicates no statistically significant differences
(ANOVA) in the frequency of CD44 expressing cells between genotypes. Black
circles indicate individuals; Black Square indicates mean value of group with 95%
confidence intervals indicated by error bars.
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Figure 3.23 Diminished Expression of Two Alternate Transcripts of CD44 in
Ets1AVil but not Ets1 s->A Mice. RT-PCR of total thymus cDNA revealed a
reduction in expression of two transcripts of CD44 in Ets1 ~ VII thymocytes
(VIINII). The transcripts are normally expressed in wild type mice (+1+). Ets1 s ->A
mice (SAlSA) show similar levels to wild type mice. HPRT loading control is
shown.
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in Ets1 s ->A mice, again consistent with the Ets1/RUNX1 coordinate model.
That is, assuming CD44 is a direct target of Ets1 as predicted by promoter
analysis, loss of CD44 expression in

Ets1~VII

mice most likely arises from the

loss of coordinate binding of Runx1 with Ets1 on the three composite
RunxlEts binding sites. An alternate splice form of CD44 is detectible in the
thymus using this primer set. CD44 is extensively regulated by alternative
splicing (Gunthert 1993), and the loss of expression of multiple forms is
suggestive that this reduced CD44 expression represents a global reduction
in CD44 expression as opposed to the loss of a particular splice form.
Collectively the Csf2 and CD44 expression data would suggest that increased
expression of Runx1 and/or other Runx1 protein partners do not compensate
for loss of full-length Ets1 in the thymus. Given that a role for Ets1 ~VII in
transcriptional repression has not been reported, these data also suggest that
the thymic phenotype is not due solely to the overexpression of the

Ets1~VII

isoform, but instead indicate a requirement for full-length Ets1 in the
expression of Csf2 and CD44 when considering the simplest (direct)
regulation by Ets1. It should be said that under physiological conditions where
both full-length and

Ets1~VII

proteins are expressed, the ~VII form likely does

serve to limit expression on promoters that benefit from exon VII domaindependent coordinate transcription. Such inhibition would involve competitive
binding of the !J.VII form to the EBS, thereby competitively blocking the
potential for synergistic transcription by the full-length form. This can not be
the case, however, in Ets1 ~ VII homozygotes, as these mice lack expression
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of the full-length form thereby obviating the role for competitive binding. Thus
the overexpression of the Ets1 ~ VII form seen in our Ets1 ~ VII homozygotes is
less likely to account for the diminished expression of Csf2 and CD44
transcripts.

3.2 Microsplenia

3.2.1 Organ Weight Analysis
A statistically significant 34% decrease in the spleen weight in Ets1 f1VIl/f1VII
mice was confirmed by ANOVA, p=0.00006 (Fig 3.24). This phenotype was
independent of changes in total body mass. Mean spleen: body mass in
homozygotes was 31.5% reduced from wild type mean, p<0.00013 (Fig 3.25).
Ets1~VII

.

heterozygotes were indistinguishable from wild-type mice by spleen

organ weight analysis, with

Ets1~VII

homozygotes having spleen weights

34% reduced from heterozygotes (p=0.000128, 2 tailed t-test). After
normalizing organ weight to body weight, however, heterozygotes exhibited
an intermediate phenotype. Normalized spleen:bodyweight was 130/0 reduced
from wild-type mice (ns, t-test), but 21 % larger than the spleen:bodyweight of
homozygotes (p=0.01 02; t-test). No alterations in spleen size were detected
in preliminary analysis of Ets1 S->A mice (Fig 3.26).
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Figure 3.24 Microsplenia in Ets1AVil Mice is More Severe in Male Mice.
Spleen mass of 7-21 week old 129 strain mice is plotted by genotype and
gender. Black circles represent individual female mice and dashes represent
individual male mice. Total, female and male means are represented by black
box, white circle and white boxes respectively, ± standard deviation.
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Spleen: Body Weight Ratio by Gender and Genotype in
7-21 Week Old Mice
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Figure 3.25 Microsplenia in Ets1AVil Mice is Independent of Total Body
Mass. Spleen:body mass of 7-21 week old 129 strain mice is plotted by
genotype and gender. Black circles represent individual female mice and dashes
represent individual male mice. Total, female and male means are represented
by black box, white circle and white boxes respectively, ± standard deviation.
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Ets1S->A Spleen Weight by Genotype
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Figure 3.26 No Significant Change in Spleen Size of Ets1 s ->A Homozygotes.
Spleen mass of adult mice is plotted by genotype. Black circles indicate
individuals; Black Square indicates mean value of group with 95% confidence
intervals indicated by error bars. This distribution was found not statistically
significant by one-way ANOVA.
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3.2.2 Cell Type Distribution
No statistically significant alteration in the relative frequency of lymphoid
derived cells was observed in homozygotes relative to wild type littermates
(CD19+ B cells, CD94+NK cells, CD4+ T cells, CD8+ T cells, Fig 3.27).
However, when compared based upon calculated cell mass, statistically
significant differences in cell type distribution were observed. Calculated cell
mass was determined as the product of the relative frequency of cells
(number of cells/10 4 events) by total organ weight. This was done as a proxy
for the conventional method of taking the product of the estimated total cell
number and multiplying by the relative frequency of cells to determine
absolute cell number. Such calculation of cell numbers was not done because
in some assays clumps of apoptotic cells precluded accurate determination of
cell numbers. The use of such a calculated value, rather than relative
frequency alone, is important because relative frequency alone can not
identify an affected cell population. For instance normal numbers of a cell
type (e.g. CD4+CD8- thymocytes) may appear as an increased or decreased
relative frequency due to the overall contraction or expansion of the cellular
compartment being assayed (e.g. total thymocytes). Thus, cell count or
calculated mass values offer needed context for the interpretation of relative
values. When calculated on a cell mass basis, reductions in both Band T
lymphocyte populations were observed. Cell mass attributable to the B cell
compartment was reduced 34% in

Ets1~ VII

spleens relative to wild type

(p<O.05), and CD4+ and CD8+ T cell compartment mass was reduced 29%
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Figure 3.27 Microsplenia of Ets1AVil is Attributable to Reduced Numbers of
Lymphocytes. A. Table summarizing results of two color flow cytometry of
lymphoid cells of the spleen by CD4/CD8 or CD19/CD94 labeling of splenocytes
from 8-16 week old 129 strain Ets1~VII targeted mice and wild type littermates.
Left half (gray) shows average relative percentages of each population, based
upon 104 cell counts/mouse. Right side shows mean calculated cell mass for
each population, calculated as the product of mean relative percentage of each
mouse and spleen weight. Relative increase or decrease of mean Ets1 ~ VII
values compared to wild type values are indicated at the bottom of the chart. 0-=
standard deviation, n= number of individual mice assayed. B. Representative dot
plots of either CD4/CD8 or CD19/CD94 double labeled splenocytes from
Ets1 ~ VII and wild type mice. Relative percentages indicated in each quadrant.
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and 380/0 respectively (p<O.01, Fig3.27-28). These results are similar to the
22% and 440/0 reductions in cell numbers reported for Ets1 knockout mice
(Barton, Muthusamyet al. 1998). Thus our microsplenia phenotype appears
largely similar to the phenotype observed in Ets1 null animals, while our
thymomegaly phenotype contrasts with the results of Ets1 null animals. There
are a number of possible explanations for such tissue specific differences in
phenotype. For instance, the thymus is a more specialized organ where T cell
development occurs, while spleen participates in a broader group of effector
functions as well as the maturation of a more diverse population of cells.
While both are organs comprised largely of hematologic cells, such distinction
in function and developmental stage necessitates distinctive cellular and
molecular programs which may differ in their requirement(s) for Ets1
expression or their tolerance for misexpression of Ets1. Even from a solely
molecular perspective, Ets 1~ VII mice represent both a transgenic
overexpression of the

Ets1~ VII

form by both relative and absolute measures,

and represent a null with respect for full-length Ets1. Given that the relative
requirements for these isoforms or their interplay are not well defined in any
tissue, neither phenotypes mirroring transgenic overexpressors or those
mirroring null would be unexpected. One similarity between the spleen and
thymus phenotypes of Ets1 ~ VII mice is that the CD8+ population is the most
severely affected in the spleen. In the myeloid compartment, again there were
no statistically significant alterations in the relative percentages of
splenocytes on a cell mass basis; however there was a trend towards

124

Spleen Weight Normalized COS'" Splenocytes by

A

Genotype
¢l

1()OO

~

sg

900

8...

8frO

1l,.

700

e

~

4>
S>-

:;l

,2

~

500
400

e

2110

rs

100

;

1••

o

X
~

~

I

106

•

300

38 .4 .

•

0

+1

B

•

<,

VII1+

Spleen \'\eight Normalized C04+ Sptenocyte$ by
Genotype

•

1142

t»

> 1500

fI

& 1000

><

ig

•
•

••

l:::l
r.I

•
1240t :

••

500
" p<:O 006

''is.

!/)

0
i\VIltAVU

c

Spleen Mass Norn1aliz:ed 0 0 19'" Splenocytes by

Genotype
4000

•

308a t a

•

•

•

2041

f•
, p<:.O.0176

+1+

tl VltJ+

AVHh VIl

Figure 3.28 Statistically Significant Splenic Lymphocyte Cell Type
Distributions. A . Calculated cell mass decrease inCD8+ splenocytes of
homozygotes B. Decreases in CID4+ splenocytes on a cell mass basis. C.
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125

increased proportion of myeloid cells,(Gr-1 + and/or Mac1 +, Fig 3.29).
Calculated on the basis of estimated cell mass there was a 42% decrease in
cells lacking myeloid markers (Gr-1-Mac1-, p<0.01, 3.29-30). Taken together
these results suggest that the underlying microsplenia phenotype in Ets1 ~ VII
mice primarily is due to decrease in lymphoid derived cells.

3.2.3 Mechanistic Basis
In order to establish the etiology of the microsplenia in Ets 1AVII mice we
assessed cell proliferation, apoptosis, and cell size. No significant differences
in cell size were detected by comparison of mean forward scatter (FSC) of
freshly isolated splenocytes irrespective of genotype.

3.2.3.1 Proliferation
As described for studies in the thymus of Ets1AVil mice, BrdU and PCNA
were used as markers to study proliferation in the spleen. By BrdU
incorporation spleens of homozygotes were found to have a marked increase
in the proliferation of splenocytes in the red pulp. In normal mice, the red pulp
is comprised of a heterogeneous mixture of cells (including myeloid cells)
while the predominant localization of lymphocytes is in the white pulp
(alternately known as periarteriolar lymphatic sheath; PALS). Given our cell
type distribution data, which indicated a reduced lymphoid compartment of
the spleen but normal myeloid compartment size, this proliferation in the red
pulp may indicate either an ineffective homeostatic proliferation of ectopically
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counts/mouse. B. Calculated cell mass for each population, calculated as the
product of mean relative percentage of each mouse and spleen weight. Relative
increase or decrease of mean Ets1 i\VII values compared to wild type values are
indicated at the bottom of the chart. Values represent means from 4 individuals,
0= standard deviation. C. Representative dot plots of Gr-1/Mac1 double labeled
splenocytes from Ets1 i\ VII and wild type mice. Relative percentages indicated in
each quadrant.
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localized lymphocytes, or a proliferation of myeloid cells of the red pulp that
maintains normal compartment size in response to some stressor that
globally reduces the number of hematologic cells in the spleen (Fig 3.31).
Normal homeostatic proliferation of naive splenic lymphocytes may require
migration to the white pulp. Specifically, inactivation of chemokine receptors
(Le. CCR7) by inhibiting G-proteins with pertussis toxin (PTX) has been
shown to block both migration of adoptively transferred na·ive lymphocytes to
the white pulp and their homeostatic proliferation in irradiated hosts (Dummer,
Ernst et al. 2001). This may suggest that the red pulp of the spleen does not
provide a suitable microenvironment for homeostatic proliferation, and that
homeostatic proliferation initiated in this region may be ineffective. No
obvious change in proliferation was observed in the white pulp splenocytes,
with germinal centers being observed in both wild type and homozygotes.
These BrdU IHC results were confirmed by PCNA immunohistochemistry (Fig
3.32) with

Ets1~ VII

mice having a similarly dramatic increase in red pulp

proliferation. Interestingly, and perhaps coincidentally, more germinal centers
seemed to be present in the

Ets1~VII

spleens relative to wild type mice when

measured by PCNA. Taken together these results argue that expressing only
the

Ets1~ VII

isoform either favors a broad microsplenia affecting both

lymphoid an9 myeloid lineages with myeloid cell numbers maintained at
homeostatic levels by proliferation in the red pulp, or that the spleens of
Ets1~ VII

mice are Iymphopenic and the failure to maintain normal numbers of
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40x

Figure 3.31 Marked Increase in Cell Proliferation in the Splenic Red Pulp of
Ets1AVil Mice. BrdU staining of 7uM spleen sections from wild type (A) and
Ets1~VII homozygotes (B), respectively, demonstrates marked increase in
proliferation in the red pulp of the spleen of homozygotes. Hematoxylin stain.
GC= germinal center, WP= white pulp, RP= Red pulp.
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Figure 3.32 Increased Proliferation of Ets1AVil Splenocytes Detected by
peNA IHe. Comparative PCNA staining of 7uM sections of wild type (A) and
Ets1 ~ VII spleen (e) reveals marked increase in red pulp splenocyte proliferation
in Ets1~ VII mice. Serial sections not treated with PCNA antibody served as
negative controls, pictured for wild type 40x (8), Ets 1~ VII homozygote 40x (D),
GC= germinal center, RP= red pulp, WP= white pulp.
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splenic lymphocytes is associated with an ineffective proliferative response
characterized by ectopic localization of proliferative lymphocytes in the red
pulp.

3.2.3.2 Apoptosis
Apoptosis is critical to the regulation of the peripheral lymphocyte
homeostasis, both in limiting the number of peripheral lymphocytes and in the
regulation of the affinity/avidity and diversity of the antigen receptor pool
(Green, Droin et al. 2003). As described for studies in the thymus, annexin V
staining was used to measure the frequency of apoptosis in splenocytes.
Annexin V staining of primary splenocytes from

Ets1~VII

heterozygous

intercross littermates showed a two-fold mean elevation in the frequency of
apoptosis in the spleens of homozygotes relative to either heterozygotes or
wild-type mice (Fig 3.33-34, p<0.001). Given the marked increase in
apoptotic cells in homozygotes, it is likely that apoptosis is primary to the
microsplenic phenotype. Absent such a dramatic change in the rate of
apoptosis the previously observed increase in proliferation in microsplenia
would seem paradoxical. The increased apoptosis observed in

Ets1~VII

mice,

together with diminished spleen size suggest an apoptosis-limited proliferative
response to lymphopenia. Given the 30-40% reduction in lymphoid mean
splenocyte mass in homozygotes it is likely that this increased rate of
apoptosis corresponds to T and B cell apoptosis. Collectively these results
implicate a role for the full-length isoform of Ets1 in the regulation of
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Figure 3.33 Pronounced Increase in the Apoptotic Rate in Ets1AVil Spleens.
A. Merged histogram demonstrating increased apoptosis in Ets1!1VII splenocytes
relative to wild type littermates. B, C, 0 Representative histograms of annexin V
staining of wild type, heterozygote and homozygote splenocytes respectively with
percentages of apoptotic cells indicated.
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134

lymphocyte apoptosis, though it remains to be determined if this apoptosis is
a direct effect, or secondary to other cellular dysfunction.

3.2.4 Molecular Basis
As previously discussed (section 3.1.4.1) we have demonstrated that normal
expression of Cdkn2a and Cdkn1 b may require transcriptional activation by
full-length Ets1, and that the absence of this isoform in the thymus of Ets1 ilVII
homozygotes results in reduced expression of Cdkn2a and Cdkn1 b. The
reduced expression of these cell cycle inhibitors has thereby been implicated
in the increased thymocyte proliferation observed by PCNA and BrdU IHC.
Given their implication in thymocyte proliferation, the expression of Cdkn2a
and Cdkn1 b was assessed in the spleens of Ets1ilVil mice. Given that the
organ weight analysis suggests opposing phenotypes in the thymus and
spleen and that the transcriptional regulation of these genes observed in the
thymus supports the possibility that they are direct Ets1 targets, we expected
that these genes might be upregulated in the spleens of Ets1ilVil mice.
Western blot analysis of total splenocytes from Ets1il VII homozygotes and
heterozygotes shows decreased expression of Cdkn1 b relative to wild type
littermates (Fig 3.35 top). Consistent with this diminished Cdkn1b protein
expression, Ets1 ilVII spleens show diminished expression of Cdkn1 b
transcripts on cDNA from total spleen RNA as detected by RT -PCR (Fig 3.35
bottom). As with the thymus this suggests a role for Ets1 isoform-specific
regulation of Cdkn1b transcription. Though this reduction in expression is
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Figure 3.35 Analysis of CDKN1b Protein and Transcript Expression in Ets1AVil
Mice. A. Western blot analysis of Ets1L\VII mice shows diminished expression of
Cdkn1 b protein in heterozygotes and homozygotes. B. RT-PCR analysis of total spleen
cDNA shows slight reduction in Cdkn1 b transcript expression in homozygotes. HPRT
loading control and (-)Template negative control s are shown.
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consistent with the observed increase in cellular proliferation demonstrated by
PCNA and BrdU IHC, it is counterintuitive to the observed microsplenia
phenotype of Ets18VII mice. The opposition of the hyperproliferative and
microsplenic phenotypes suggests that this proliferation is superseded by
other cellular processes, such as apoptosis (e.g. Fig 3.33) or cell emigration,
which serve to limit spleen size. Ets1 S->A splenocytes show no appreciable
alteration in Cdkn1 b transcript levels by RT-PCR (Fig 3.36), suggesting
similar mechanistic regulation of Ets1 isoforms exists in the spleen as in the
thymus. That is, either Ets1 is not a direct transcriptional regulator of Cdkn1 b
or that full-length Ets1 augmented transcription is required for normal
expression of the Cdkn1 b gene. Levels of Cdkn2a transcripts were reduced in
the spleens of Ets1L\VII mice (Fig 3.37). Thus, as with the thymus, it is likely
that diminished expression of Cdkn1 band Cdkn2a contribute to the increased
cell proliferation observed in the red pulp of Ets1 L\ VII spleens. Interestingly,
the Ets1 S->A splenocytes do not show the upregulation of Cdkn2a relative to
wild-type mice that was observed in the thymus. This difference suggests that
there may be distinctions between the thymus and the spleen with respect to
propensity for, or responsiveness to, calcium flux. For instance such
distinction may be due to the different developmental stages of the
lymphocytes in each respective compartment. Further supporting this idea,
there is no obvious direct mechanism whereby S->A mutant Ets1
transcriptional activity should be intermediate between wild-type and Ets1 L\ VII
only, since absent additional (indirect) regulation S->A conversion is only
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Figure 3.36 Cdkn1 b Transcript Expression in Ets1 S->A Spleens. RT -PCR
analysis of total spleen cDNA shows no change in expression of Cdkn1 b in
homozygotes relative to wild type littermates. HPRT loading control.
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Figure 3.37 Reduced Expression of Cdkn2a Transcripts in Ets1AVil Spleen.
RT-PCR analysis of total spleen cDNA from Ets1~VII and Ets1 s ->A mice shows
reduced expression in Ets1 ~ VII but not Ets1 S->A mice. HPRT loading control is
shown.
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known to be an activating (escape from repression) mutation. Taken together
these data suggest that similar molecular mechanisms underlie the increased
proliferation of both thymocytes and splenocytes. The genes directly
regulating apoptosis have not yet been studied in these mice.

3.3 Peripheral Lymphocyte Homeostatic Proliferation

3.3.1 Loss of Splenic Memory Cells
In the periphery, high level of CD44 expression is a marker of cells
undergoing homeostatic proliferation or memory cells. In normal mice CD44 hi
memory cells account for 10-200/0 of peripheral cells (Sprent 2003).
Consistent with this, flow cytometric analysis of splenocytes from wild-type
mice revealed 8-180/0 of cells to be CD44 hi (Fig 3.38-39). In marked contrast,
Ets1AVil heterozygotes and homozygotes showed a 50% reduction in the
mean relative frequency of these cells (CD44 Hi cells/104 events). This
phenotype is even more pronounced when considering that affected mice
have microsplenia, and thus this relative frequency corresponds to an even
lower absolute number of cells. While it is not clear the relative contributions
of memory cells or cells undergoing homeostatic proliferation accounting for
the remaining CD44hi splenocytes in homozygotes, two things are clear.
There are fewer cells in Ets1AVil mice with the memory phenotype than
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Figure 3.38 Diminished CD44Hi Splenocyte Population Suggests Defective
Activation or Memory Cell Generation in Ets1AVil Mice. Representative flow
cytometric determination of CD44 expression on splenocytes reveals a marked
reduction in the CD44 Hi population of cells in heterozygote and homozygote
spleens. A. Merged historgram Green= wild type, blue= heterozygote, red=
homozygote. B, C, D Illustrate representative flow cytometric histograms with
percentages of CD44 Hi cells indicated for wild type, heterozygotes and
homozygotes respectively.
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would be expected in normal mice, and there is a failure of homeostatic
proliferation to maintain proper numbers of peripheral lymphocytes.
Collectively these indicate an isoform specific requirement for full-length Ets1
(or a requirement for the control of relative levels of expression of both fulllength Ets1 and

Ets1~VII

isoforms) in the control of normal T cell homeostasis

and function. To determine if this memory phenotype in

Ets1~ VII

mice is due,

at least in part to transcriptional misregulation of RUNX1/Ets1 coordinately
regulated target genes (and thereby be consistent with expression analysis
results and model in the thymus) CD44 expression was assessed. For this
study, RT-PCR on cDNA from total thymus extract was conducted, using the
same primers described previously. By this approach, a clear loss of or
marked reduction in CD44 transcripts was observed in

Ets1~ VII

mice relative

to wild-type littermates (Fig 3.40). Expression of CD44 was unaffected in
Ets1 s->A mice, again consistent with the thymus results and Ets1/RUNX1
coordinate model. In the periphery, CD44 expression is a marker of activated
cells, memory cells, and cells undergoing homeostatic proliferation. In order
to assess loss of memory cell function in these mice, mice were vaccinated
. with MVA strain vaccinia virus, followed by a challenge one week later. The
day following challenge IFN-y production was found to be elevated in wildtype mice, while IFN-y levels in

Ets1~VII

homozygotes was found to be

equivalent to baseline unchallenged mice (Fig 3.41). This rapid IFN-y
response is a measure of memory cell activity, indicating that memory cell
presence or activity was deficient in

Ets1~ VII
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mice (Liu and Whitton 2005). It

....ro
Q)

Spleen

- +
+

+
+

<: <:

«
en

«
en

> >

en

en

~

~

a.
E
Q)

-

r-

I
-..-

CD44

HPRT

30 Cycles

Figure 3.40 Diminished Expression of CD44 Transcripts in Ets1AVil But Not
Ets1 s->A Mice. RT-PCR of total spleen cDNA revealed a reduction in expression
of CD44 transcripts in Ets1~ VII splenocytes (VIINII). The transcripts are normally
expressed in wild type mice (+/+). Ets1 S->A mice (SAlSA) show similar levels to
wild type mice. HPRT loading control and No template negative controls are
shown.
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Comparison of Serum IFNy Levels in Vaccinated Mice
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Figure 3.41 Defective Production of IFN-y in Ets1AVII Mice. Mice were
vaccinated with MVA-Strain vaccinia virus, and given a boost 7 days later. IFN-y
production was measured 24 hours post boost by ELISA. Homozygotes do not
produce IFN-y in response to challenge.
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remains to be determined whether C044 misexpression plays a causal role in
the thymomegaly and microsplenia of

Ets1~VII

mice. We have provided

evidence supporting a direct role for full-length Ets1 in the transcriptional
regulation of C044, by a RUNX1/Ets1 coordinate transcription model. That is
full-length Ets1, but not

Ets1~VII,

is capable of binding to juxtaposed Runx

and Ets binding sites identified in the C044 promoter to increase transcription
of CD44 in thymocytes and splenocytes. The reduction of C044 expression
observed in Ets1 ~VII mice results from the inability to augment transcription
by protein partnering with Runx1. This transcriptional deficit is not fully
rescued by post-transcriptional regulation, as the cell surface expression of
CD44 is also diminished.

3.3.2 Decreased Peripheral Lymphocyte Numbers
The definitive measure of defective homeostatic proliferation is persistent
lymphopenia beyond the removal of lymphopenia inducing stress. Splenic
defects in

Ets1~ VII

mice, including increased rate of splenocyte apoptosis,

microsplenia, and diminished relative percentage and calculated cell mass of
splenic lymphocytes reflects a profound reduction of lymphoid cells of the
spleen (Fig 3.27-30). Given that the spleen, as well as lymph nodes,
constitutes part of the peripheral lymphoid compartment the observed
microsplenia phenotype in

Ets1~ VII

mice suggests a larger peripheral

lymphopenia. That is, given that the spleen is part of the peripheral
circulation, reductions in lymphocyte populations here are likely reflective of
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diminished circulating peripheral lymphocyte numbers as well excepting the
possibility of defects in homing/migration. Flow cytometric analysis confirmed
an incompletely penetrant peripheral lymphopenia in Ets1L\VII mice.
Specifically, three of eight homozygous mutant mice analyzed demonstrated
a relative 1300/0 increase in the proportion of Gr-1 +Mac1 + cells (Fig 3.42).
Normalized to blood cell count, this represented an approximate 500/0
reduction in circulating peripheral lymphocytes. In Ets1 s->A mice, however,
there were no overt changes in the representation of circulating cells (Fig
3.43). We have provided evidence for a peripheral lymphopenia in the spleen
and of variable penetrance in circulation. The reason for variable penetrance
with this phenotype is not immediately clear. This may reflect the possible
involvement of environmental factors, stochastic processes, or a role for Ets1
as a modifier rather than the root of an immuno-pathology. This reduction in
lymphocyte numbers is coincident with increased rates of cellular proliferation
and apoptosis, suggestive that homeostatic proliferation of lymphocytes is
initiated but unsuccessful. The idea of such defective homeostatic
prOliferation is further strengthened by a marked reduction in cells expressing
high levels of CD44. CD44 hi memory cells or na"ive cells acquiring a CD44 hi
phenotype are required for homeostatic proliferation. In total our data
suggests the presence of a thymopoietic defect in Ets1L1VII mice, which
results in peripheral lymphopenia and defective homeostatic proliferation of
peripheral lymphocytes.
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Relative Increase in Peripheral Granulocyte Number in Ets1AVil Homozygotes
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Figure 3.42 Analysis of Myeloid Cells of Ets1AVil Peripheral Blood by Flow
Cytometry. Retro-orbital collection of peripheral blood from 12 week old 129
strain mice revealed increased relative percentage of GR-1 +Mac-1 + cells. These
cells correspond to reduced numbers of total blood leukocytes, indicating
peripheral lymphopenia.
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Figure 3.43. Flow Cytometric Analysis of Ets1 s->A Peripheral Blood. No
significant alterations in the relative pro£ortions of lymphoid or myeloid cells were
observed in 8-12 week 129 strain Ets1 ->Amice. A. Summary table of mean
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deviation, n= number of individual mice assayed. B. Graphical depiction of
results, black circles represent individuals, black boxes represent mean values
with 95% confidence interval shown as error bars.
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Chapter 4: Summary and Future Directions
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4.1 Summary
4.1.1 Generation of Ets1 Allelic Series
At the outset of this project gene targeting studies in mice had already
demonstrated a requirement for Ets1 in normal immune function (Bories,
Willerford et al. 1995; Muthusamy, Barton et al. 1995). Lacking however, was
an understanding of how the interplay of the two Ets1 isoforms contributed to
mediate these functions. Indeed, in vitro studies had demonstrated that these
two isoforms had differing biophysical properties (Fisher, Fivash et al. 1994),
but the idea that perturbations in the balance of these isoforms could result in
distinct physiological changes had only recently gained support from seminal
work demonstrating these isoforms had differing capacity to induce apoptosis
in a colon cancer cell line (Li, Pei et al. 1999). We have generated an allelic
series of Ets1 mutant mice that directly demonstrate the physiological
consequences of altering the balance of Ets1 isoforms, and further allow
phenotypes to be classified as serine-phosphorylation dependent or
independent. To date the series of mice includes Ets1 L\ VII mice which lack
the entire exon VII domain, and the Ets1 S->A mice which lack key
phosphorylatable serine residues required for activating the repressor
functions of the exon VII coded domain. Progress has also been made
towards the generation of a third line of mice that will be capable of producing
only the full-length isoform of Ets1 to ascribe functions exclusive to the
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Ets1 ~ VII isoform. Collectively these mice demonstrate the necessary and
sufficient roles for each isoform, and demonstrate the mode of action of the
exon VII domain required for these functions. Moreover, given the growing
body of literature supporting Ets1 isoform specific modulation in immune
function, angiogenesis, invasive neoplasia, extracellular matrix remodeling,
and apoptosis these mice will likely have broad relevance to both basic and
clinical science (Li, Pei et al. 1999; Baillat, Begue et al. 2002; Ballschmieter,
Braig et al. 2003; Elvert, Kappel et al. 2003; Lionneton, Lelievre et al. 2003;
Liu, Holm et al. 2004).

4.1.2 Relevance of Ets1 Gene Targeted Mice in Comparative Medicine
Herein we have described the generation and preliminarly phenotypic
analysis of Ets1 gene targeted mice which introduce precise mutations to
disrupt Ets1 isoform balance, in terms of both function and expression. While
evidence has associated alterations in Ets1 expression with clinical
pathologies in humans such as insulin-dependent diabetes mellitus
(Japanese patients) (Aparicio 1991), systemic lupus erythematosus (as a
modifier of disease presentation) (Sullivan, Piliero et al. 2000), and leukemias
(involving cytogenetic abnormalities) (Diaz, Le Beau et al. 1986; Rovigatti,
Watson et al. 1986; Sacchi, Watson et al. 1986; Goyns, Hann et al. 1987) a
causal role for Ets1 has not been identified in human disease (OMIM
#164720) (Hamosh, Scott et al. 2005). Furthermore, such association studies
have only recently begun to distinguish between the full-length and
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Ets1~VII

isoforms (Buggy, Maguire et al. 2004). Significantly, our work has
demonstrated that multiple pathologies arise from genetic ablation of 2.3 kb of
genomic sequence containing exon VII of Ets1 (261 bp) and of flanking
intronic sequence (2.1 kb) in mice. These results provide strong evidence that
Ets1 isoform misregulation is sufficient to cause the immunologic pathologies
of thymomegaly, microsplenia, peripheral lymphopenia, defective lymphocyte
homeostatic proliferation and defective memory cell generation reported here,
as well as cardiovascular and nerological pathologies which were also
observed but not reported. As a standard caveat of comparative medicine, the
possibility that these results are unique to the murine system exists. In our
model the liklihood of such species specific limitation is diminished, however,
by the high degree of conservation of the immune system, the ets gene
family, and the Ets1 gene structure and regulation between mouse and
human. Evidence supporting a high degree of conservation between the
mouse and human immune system include that mice are susceptible to a
similar range of pathogens as humans, and the immune response elicited
contains both rapid innate and memory-generating adaptive responses
analogous to humans (Buer and Balling 2003). The latter is particularly
relevant in that the reduced CD44 expression and INF-y secretion in

Ets1~VII

mice (see section 3.3.1) indicates defective immunologic memory results from
misregulation of Ets1 isoforms. Human-mouse similarity also extends to the
Ets transcription factor family, with 26 of 27 Ets genes having murine
orthologs and no murine Ets genes lacking a human ortholog (Maglott, Ostell
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et al. 2005). Thus it is unlikely that any compensation by redundant function
of other Ets family members to the engineered Ets1 mutation is species
specific. Furthermore, Ets1 genomic structure is highly conserved in mouse
and man. The Ets1 gene is located within a mouse-human syntenic region
(Spyropoulos, Bartel et al. 2003) with both mouse and human genes
consisting of 8 exons (Jorcyk, Watson et al. 1991). In both species the Ets1
gene has been shown to produce multiple transcripts arising from differential
polyadenylation, multiple transcription initiation sites, and alternative splicing
(Collyn d'Hooghe, Galiegue-Zouitina et al. 1993; Bellacosa, Datta et al. 1994).
Furthermore, both species generate alternatively spliced Ets1 transcripts
derived from alternatively skipping exon IV, exon VII, or exon IV and VII
(Jorcyk, Watson et al. 1991) to generate two protein isoforms of Ets1: the
exon VII splice variant

(Ets1~ VII)

and the full-length Ets1 (Koizumi, Fisher et

al. 1990; Jorcyk, Watson et al. 1991; Fisher, Koizumi et al. 1992). These
proteins are highly conserved across species, with 97% sequence identity
between human and mouse at the amino acid level (GenBank: P14921,
P27577). Accordingly, functional domains of Ets1 are similarly conserved
across species.

4.1.3 Phenotypic Characterization of Ets1 Mutant Mice
Gross anatomical analysis led us to study first to the lymphoid phenotype of
Ets1~VII

mutant mice. This phenotypic analysis of Ets1 mutant mice has

revealed a role for Ets1 isoform specific function in autoregulation, lymphoid
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organ size, lymphoid cell proliferation and apoptosis, as well as homeostatic
regulation of lymphoid cell number and memory cell generation, in addition to
other roles not discussed in this manuscript.

4.1.3.1 Ets1 Autoregulation
Previous in vitro studies demonstrated that the Ets1!!"VII isoform may be more
transcriptionally active on some promoters, such as VE-Cadherin, than the
full-length isoform of Ets1. However, analysis of VE-Cadherin transcript
expression in vivo from thymus and spleen of Ets1!!"VII mice did not reveal the
expected increase in expression that would be predicted from the in vitro data
(Fig 4.1). Ets1 is known to be active on its own promoter to regulate its own
transcription, and therefore its transcription could be subject to exon VII
mediated autoregulation (Oka, Rairkar et al. 1991). We did discover that the
Ets1 gene is more highly expressed at both transcript and protein levels in
vivo in both Ets1!!"VII mice and Ets1 S->A mice. One simple mechanistic
explanation for the increase of expression in Ets1!!"VIl mice would be that the
Ets1 promoter may be an in vivo example of a cis-regulatory element that is
more responsive to Ets1!!,.VII than full-length Ets1, as described for VECadherin in vitro. Given that Ets1 S->A mice also exhibit increased expression
of Ets1 transcripts and proteins, however, there must be a role for
phosphorylation mediated autoinhibition of Ets1 in this process. Both of these
model systems lack responsiveness to inhibitory signals, either by lacking the
!!,.VII coded inhibitory domain completely or lacking the key phosphorylatable
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VE-Cadherin Expression in Thymus of Ets1 Mutant Mice
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Figure 4.1 RT -PCR Analysis of VE-Cadherin Expression in Ets1AVil and
Ets1 s->A mice. Top: total thymus or spleen cDNA from wild type, Ets1L\VII or
Ets1 s ->A mice as measured by RT-PCR using VE-Cadherin primer set, and
HPRT control. Bottom: Changes in expression were found to be statistically
insignificant by densitometry.
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residues of this domain required for activation/potentiation of the repressor
functions of this domain in response to phosphorylation. This suggests that basal
regulation of Ets1 expression in thymocytes and unstimulated splenocytes is
limited by phosphorylation mediated repression as has been demonstrated in
activated cells (Bhat, Thompson et al. 1990; Rabault and Ghysdael 1994).
SpeCifically, Ets1 expression pattern has been shown to be higher in resting T
cells and expression is rapidly diminished upon activation of those cells. TCR
initiated signal is mediated by multiple signaling pathways, but most importantly
uses Ca2+ as a second messenger. This calcium flux would be expected to result
in the phosphorylation of the exon VII coded domain of Ets1, leading to rapid loss
of Ets1 DNA binding and transcriptional activities (Fisher, Ghysdael et al. 1991).
It was not known, however, if inhibition of Ets1 activity would significantly alter
expression of transcripts from the Ets1 gene. Herein we have shown that loss of
such repression leads to a dramatic increase in Ets1 transcript expression (Fig
2.8, Fig 2.14). Interestingly this is most pronounced for the Ets1AVil transcript,
even in the Ets1 S->A mice. The regulation of expression of alternatively spliced
Ets1 transcripts is not well understood, so the significance of the more
pronounced upregulation of the Ets1AVil transcript relative to full-length transcript
in Ets1 s->A mice will require further study. It is tempting to speculate that a
minimal phenotype in Ets1 S->A mice despite marked increase in Ets1 AVII
transcript expression is suggestive of the primacy of the loss of full-length Ets1 to
the phenotype of Ets 1AVII mice rather than the upregulation of the AVII
expression. Such speculation is countered, however, by the relatively modest
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upregulation of the Ets1 ~VII protein in Ets1 S->A mice relative to Ets1 ~ VII mice
(Fig 2.9 vs. Fig 2.15), potentially allowing for a threshold effect (e.g. by interfering
with the activities of other co-expressed Ets family members). The upregulation
of Ets1 in Ets1 S->A mice is more dramatic in the spleen than in the thymus. The
tissue specific modulation of this phenotype in Ets1 S->A mice relative to the
more constitutive phenotype seen in complete loss of full-length Ets1 in

Ets1~ VII

mice is likely reflective of the more subtle nature of this mutation (it allows
expression of both isoforms and protein partnering for instance). While more
complex feedback mechanisms could account for the marked increased
expression of Ets1 in Ets1~VII and Ets1 s->Alymphoid organs in both
heterozygous and homozygous mutant mice, the simplest and most direct
explanation is that Ets1 exerts positive feedback on its own promoter to maintain
expression of both Ets1 isoforms. Signals involving calcium flux, serine
phosphorylation inducing stimuli, or other factors modulating full-length Ets1mediated positive autoregulation of transcription thereby result in repression of
Ets1 expression. In this model the basal expression of

Ets1~VII

in Wild-type mice

suggests that there must be a threshold below which Ets1~VII is not capable of
generating a positive feedback loop on its own promoter. For instance one
means by which this might be achieved is by the presence of an EBS in the Ets1
promoter that has only weak affinity for Ets1~VII, but becomes fully occupied at
high concentrations of Ets1 ~VII protein. Further implication is that the level of
expression of Ets1~VII reflects the global responsiveness of Ets1 to repressive
phosphorylation feedback, such that beyond a given threshold of Ets1 ~VII
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expression Ets1 activity (an in this specific example expression as well) is not
responsive to such repression. This is illustrated by identical protein expression
patterns in the Ets1 s->Aheterozygotes and homozygotes at the protein level (Fig
2.15). In both thymus and spleen, increased expression of Ets1AVil is observed
in both heterozygotes and homozygotes, and protein expression levels are nearly
identical to each other, and elevated relative to wild-type expression (at least with
respect to the AVII form in the thymus, and for both isoforms in the spleen). This
occurs despite the presence of one wild-type full-length Ets1 allele in the
heterozygotes, which would still be fully responsive to phosphorylation mediated
inhibition. While we have proposed a threshold effect may explain a
transcriptional basis for our observed Ets1 expression pattems, other contributing
factors may include differential protein stability (or resistance to proteolysis)
and/or fundamentally different transcriptional efficiencies. Supporting a role for
these factors is the observation that Ets1AVil heterozygotes have a profound
reduction of full-length Ets1 concomitant with the massive upregulation of
Ets1AVII.

4.1.3.2 Lymphoid Organ Size
We have observed a statistically significant increase in thymus size as well as
a reduction in spleen size in Ets1AVil mice. Heterozygous mice show
intermediate to no effect depending on organ, and regardless of whether or
not organ size is normalized to total body mass. The increase in thymus size
contrasts with reports of diminished thymic cellularity in Ets1 null animals,
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while the microsplenia is consistent with reports of increased apoptosis and
diminished survival of activated lymphocytes in those animals (Bories,
Willerford et al. 1995; Muthusamy, Barton et al. 1995). Taken in aggregate
our data suggest that the thymomegaly phenotype is most likely due to
elevated expression of the

Ets1~ VII

isoform as opposed to loss of the full-

length isoform. For instance loss of both isoforms of Ets1 results in reduced
thymic cellularity whereas the gene targeted allele deleting exon VII results in
loss of full-length Ets1 and concomitant increase in Ets1 ~VII with marked
thymomegaly. However given that heterozygotes show similar upregulation of
the Ets1 ~ VII isoform, but relatively mild thymomegaly it remains likely that
full-length Ets1 moderates this phenotype. Microsplenia, conversely, is more
likely an effect of loss of full-length Ets1. As noted previously this is
consistent with Ets1 null phenotypes; but additionally Ets1 s->A mice have
upregulation of both Ets1 isoforms in the spleen but do not exhibit
microsplenia.

4.1.3.3 Regulation of Proliferation and Apoptosis
A role for Ets1 in proliferation and apoptosis was demonstrated by defective
proliferation and increased apoptosis in activated lymphocytes in Ets1 null
mice (Bories, Willerford et al. 1995; Muthusamy, Barton et al. 1995). We have
extended these findings in our studies of

Ets1~ VII

mice. Unlike Ets1 null

animals, alterations in proliferative and apoptotic indexes are seen in Ets1 ~VII
mice in unstimulated cells. Given that increased proliferation observed in the
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spleens of Ets1L.\VII is counter-intuitive to the microsplenic phenotype, it is
likely that the increased apoptotic effect is primary to microsplenia, and that
the proliferation response is compensatory. Such analysis is not as simple in
the thymus, where both the increased proliferation and reduction in apoptosis
may contribute to the thymomegaly phenotype. The mechanistic basis for
alterations in apoptosis has not yet been discovered, as well the importance
of developmental stage of lymphocytes or microenvironment cues. While the
identity of the affected populations of cells has yet to be determined, we may
speculate as to their identity. In the spleen, it is likely based upon the
observed splenic lymphopenia that these cells are lymphocytes (Fig 3.27-30).
While we have demonstrated a profound reduction in the number and activity
of CD44Hi memory celis, this population alone is unlikely to account for the
increased number of apoptotic cells (Fig 3.33-4, 38-39). In the thymus there is
a reduction in the apoptotic frequency of cells, suggesting that the simplest
explanation may be a reduction in the number of thymocytes undergoing
negative selection. In addition, we have demonstrated for the first time that
Ets1 can regulate the transcription of Cdkn1b in vivo. Additionally we are the
first to show that Ets1 regulation of Cdkn2a requires the full-length Ets1
isoform for normal expression, which may also suggest isoform specific roles
in senescence and ageing (Ohtani, Zebedee et al. 2001).
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4.1 . 3.4 Homeostatic Proliferation and Memory Cell Generation
We have presented data demonstrating reduced splenic cellularity and
variable peripheral lymphopenia. Together with the marked increase in
proliferation observed in spleens and increased apoptosis argue for a defect
in homeostatic lymphocyte proliferation. In the periphery CD44 expression is
a marker of activated cells, memory cells, and cells undergoing homeostatic
proliferation. We have demonstrated for the first time a requirement for Ets1
for the maintenance of memory cells, by reduced CD44 transcript and cellsurface expression. Preliminarily we have demonstrated loss of memory cell
function in these mice by vaccination and challenge with MVA strain vaccinia
virus which resulted in loss of IFN..y production in Ets1AVil homozygotes. This
rapid IFN-y response has been reported as a measure of memory cell activity
(Liu and Whitton 2005).

4.1.3.5 Relation of Ets1 Isoform Expression to Observed Phenotypes
The unexpected elevation in the expression of Ets1AVil protein in Ets1AVil
heterozygotes and homozygotes has complicated interpretation of
phenotypes in these mice. That is, it is unclear if a given phenotype is related
to an over representation of the AVII form, from a reduction/loss of the fulllength form, or a combination of the two. To aid in such interpretation, a table
relating observed phenotypes to Ets1 isoform expression has been compiled
(Table V). In aggregate our data suggest that the phenotypes in Ets1AVil
mice can not be attributed solely to the loss of full-length Ets1 or solely to the
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Table V. Summary of Allelic Series Phenotypes and Ets1 Expression
-t}+

VII!"

VII/VII

SAlSA

++++
+++
None
Variable-

None

NONE
+++++
NONE
++++

++

S~stemic

Lethality
Body V'/eight
Rapid IFNy Secretion
Peripheral Lymphopenia

None
+++
+++++
None

++
++++
-+
None

NO
NO
None

Th~mus

Ets1 Expression
FulI~length Ets1 Protein
Llvn Els1 Protein
Full~leogth Ets1 Transcript
Avn Ets1 Transcript
Phenotypes
Thymus Size
Thymus: Body VVeight
Proliferation
Apoptosis
Cdkn2a Protein
·Cdkn2a Transcript
Cdkn1b Protein
.Cdkn 1b Transcript
Ruox 1 Protein
Runx1 Transcript
Cst2 Transcript
C044 Transcript
CD44 Protein

+++-+
+
++++
-+

+
-f++++

-+
+
+
+++++
+++
+++
+++++
+++
+
+++
+++
++++

+++
++
ND
+++
+
NO
+
NO
++

NO
NO

+++++
+++++
+++++
++
+
+
+
++
+++
+++
+
NONE

NO
NO
NO

+

+
++++
+

NO
NO
ND
ND
++++
NO
+++

NO
++++
++++
++++

SEleen
Ets1 Expression
Full..Jength Ets1 Protein
AVII Ets1 Protein
FUll-length Ets1 Transcript
LlVIl Ets1 Transcript
Phenotypes
Spleen Size
Spleen Body v'Veight
Proliferation
Apoptosis
Cdkn2a Transcript
Cdkn 1b Protein
Cdkn1b Transcript
Runx1 Transcript
Csf2 Transcript
C044 Transcript
CD44 H ! SplenQcytes

++
+
++++
+
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+++++
NO
NO

NONE
+++++
NONE
+++

+++++
++
+++
++++

+++++
+++++
+
++
+++
+++
+++
+++
+
++++
+++++

+++++
++++

+++++

++++

+++
+++
+++++
+++++

NO

i-

++

+

+
++
++

NO

NO

NO
NO
NO
NO
+++

NO
NO
NO
+++
++

i-

++

NONE
+++

++++

NO

ND= Not Determined; * variable expression indicated 50% reduction but incomplete penetrance.
Grades range from None, and minimal (+), to maximal (+++++).
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increased expression of the AVII form. For instance, in comparing thymus
weights to Ets1 protein expression data it would seem that the phenotype
more closely mirrors the reduction in full-length Ets1 as opposed to the
elevation in AVII expression. However, the heterozygote exhibits a perfectly
intermediate effect in terms of organ size though the reduction in full-length
Ets1 expression is greater than 50% perhaps suggesting that even if
reduction of full-length Ets1 is the underlying etiology of the thymomegaly, it
may be tempered by opposition from the increased expression of the AVII
form. Moreover, given that other reports suggest increased expression of
Ets1 would predispose to a larger thymus, while loss of Ets1 would
predispose to a smaller thymus (see section 3.1.2) it may be important to
consider the possibility of a threshold effect that confounds simple
interpretation of this phenotype in terms of gradation of Ets1 isoform
expression. Specifically there may be a physiological range of Ets1
expression beyond which alterations in expression of Ets1 (either higher or
lower) will not result in further increases in thymus size (e.g. consider the
possibility of essentially full-occupancy of Ets1 binding sites in target gene
promoters upon upregulation of Ets1AVil to levels lower than observed in
Ets1AVil mice). Similarly a threshold may exist as to the upper limit of thymus
size attainable by perturbations in the molecular pathways affected in the
Ets1AVil mice. Furthermore, while the thymomegaly phenotype may closely
mirror the reduction of the full-length isoform other thymic phenotypes (i.e.
Cdkn2a and Cdkn1 b protein expression) more similarly mirror the expression
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pattern of ~VII Ets1 when comparing genotypes. Further analysis of
heterozygotes and more rigorous quantitation would aid in further
consideration of the relation of Ets1 expression gradation to phenotypes
observed in Ets1 ~ VII mice. It may be worth noting that it is not wholly
unexpected that gradation of Ets1 expression may defy easy correlation to
observed phenotypes. For instance the role for full-length Ets1 to act as a
bipartite transcription factor suggests a role for Ets1 as a modulator of the
activity of expression of other genes and as such alterations in Ets1 activity
would require consideration of factors beyond simple expression of Ets1
protein. A similar argument can be made with respect to the responsiveness
of this isoform to calcium flux. Full-length Ets1 is profoundly inhibited from
DNA binding by Ca2+ mediated phosphorylation, providing further potential for
discrepancy between activity and expression. Furthermore, Ets1 isoforms are
in competition for Ets1 binding as evidenced by their nearly identical DNA
binding site preferences (Lionneton, Lelievre et at 2003). In this respect,
graded alterations in the expression of one isoform should not be considered
to the exclusion of the expression of the other isoform.

4.1.3.6 Alterations in Alternative Splicing in Ets1AVil Mice
One of the more unexpected findings in our analysis of the Ets1 allelic series
was a seemingly widespread alteration in the representation of alternatively
spliced transcripts in gene targeted mice. This includes alterations in the
representation of splice forms in Ets1 (Figs 2.8, 2.9, 2.14 and 2.15), Runx1
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(Fig 3.17), and CD44 (Fig 3.23 and 3.40). Although a role for Ets1 in the
regulation of alternative splicing has not been reported, there are numerous
mechanisms whereby Ets1 could mediate such an effect. In order to more
clearly illustrate control points potentially influenced by Ets1, a brief overview
of mechanisms of alternative splicing may be helpful. Transcript processing
occurs both co-transcriptionally and post-transcriptionally, allowing
modulations of either transcription or splicesome formation to exert influence
on pre-mRNA splicing (Kornblihtt, de la Mata et al. 2004). The principle
effector of transcript processing, the splicesome, is a heterogeneous complex
composed of both protein and nucleic acid. It consists of 5 small nuclear
ribonuceoproteins (snRNPs; U1, U2, U4, U5, U6) as well as 50-100 non..
snRNP splicing factors(Kramer 1996; Jurica and Moore 2003). The activity of
the splicesome is regulated by accessory proteins which affect its activity
and/or stability. One such accessory group of proteins, SR proteins, is defined
by the presence of a serine-arginine rich domain (SR domain) and an RNA
binding domain (RRM domain) (Graveley 2000). These proteins tend to bind
exon splicing enhancers to promote transcript splicing (Shen, Kan et al.
2004). Another group of proteins, heterogeneous nuclear riobonucleoproteins
(hnRNP proteins), tends to antagonize transcript splicing by binding to intronic
or exonic splicing silencers (Pozzoli and Sironi 2005). RNA helicases are also
required for relieving torsional stresses generated in splicesome transcript
processing (Staley and Guthrie 1998), as well as regulating the availability of
RNA for accessory protein binding (Fairman, Maroney et al. 2004). The
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mechanisms whereby Ets1 regulates transcript processing may be broadly
divided into direct regulation of the cellular effectors of transcript processing
and indirect regulation whereby alterations in alternative splicing are
secondary to other effects mediated by Ets1. As a transcription factor Ets1
could directly regulate transcript processing by effecting transcription of any of
the above described factors with essential roles in transcript processing. Also,
given that other transcription factors are known to be present in the
splicesome and physically interact with essential components of the
splicesome (Davies, Calvio et al. 1998; Zhou, Licklider et al. 2002; Kameoka,
Duque et al. 2004), it is possible (albeit conjecturally) that in some instances
Ets1 could directly participate in transcript processing as a component of the
spiceosome. Some support for such a role is provided by the observation that
another Ets factor, Spi1, binds the splicing factor TLS (translocated in
liposarcoma) through an interaction requiring the Ets domain of Spi1 (Hallier,
Lerga et al. 1998). It should be noted, however, that the Ets domain of Fli1
(which is more similar to the Ets domain of Ets1 as shown in Figure 1.1) did
not participate in protein:protein interactions with TLS. Transcription factors
may also directly regulate alternative splicing of transcripts by promoter
choice (Kornblihtt 2005). The Ets family member Spi1 has been shown to
affect the splicing of E1 A pre-mRNA in a promoter dependent manner
(Guillouf, Gallais et al. 2006). It is also possible for Ets1 to regulate transcript
splicing by indirect means. That is, regulation of alternative splicing by Ets1
may be secondary to broader regulation of biological processes not directly
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related to spiceosome assembly or activity. As an example of such an indirect
model, a recent publication has indicated a potential role for oxidative stress
in global changes in alternative spliCing in neurons (Maracchioni, Totaro et al.
2006). This is a particularly exciting finding because we have previously
identified a role for Ets 1 in the regulation of reactive oxygen species as
evidenced by reduction in the expression of antioxidant enzymes in

Ets1~VII

mice (Fig 4.2 A), as well as markers of oxidative damage (Fig 4.2 B). We
hypothesize that the increased oxidative stress in Ets1AVil mice owes to loss
of coordinate transcriptional activation with EPAS1, which has been shown to
require the exon VII domain of Ets1 (Elvert, Kappel et at 2003) given that
mice deficient in EPAS1 are also defective in remediating oxidants
(Scortegagna, Ding et al. 2003). An alternate mechanism of indirect
regulation of transcript processing is that Ets1 exerts influence upon a
feedback mechanism (either under physiological conditions, or due to the
elevated expression of the AVII form in Ets1~VII homozygotes) that governs
the activity of kinases and/or phosphatases active in regulation of transcript
processing (e.g. phosphorylation of SR proteins, or CTD of RNA Pol II) and in
Ets1 autoinhibition. For example a role for Ca 2+ mediated phosphorylation
(through CamK IV) in the alternative splicing of the voltage gated K+ channels
of neurons has been demonstrated (Xie and Black 2001). Support for such a
phosphorylation/calcium feedback mechanism is provided by the observation
that in our Ets1 S->A mice, which are engineered to specifically lack sensitivity
to Ca2+ mediated phosphorylation, we observe Ets1 transcripts are more
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A. Reduced Expression of Antioxidant Genes in Thymocytes of Ets1ilVII Mice
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B. Diminished DDIT3 Expression in Ets1 il VII Thymocytes

Jg

DP

+
+

+

::::::::

>

CD8SP

ON

5>

::::::::

>

+
+

+

::::::::

5>

~

>

+
+

+

::::::::

5>

::::::::

> >

CD4SP

+
+

+

::::::::

>

5>

::::::::

>

co
c..
E

~
0
z

DOIT3
40 Cycles

HPRT
35 cycles

Figure 4.2 Impaired Homeostasis of Reactive Oxygen Species in Ets1AVil
Mice. A. RT-PCR on RNA from flow sorted thymocytes demonstrated a marked
reduction in the expression of the primary antioxidant enzymes, most markedly in
immature thymocyte populations. SOD1 = Superoxide Dismutase 1, SOD2=
Superoxide Dismutase 2, Cata= Catalase, Gpx1 = Glutathione Peroxidase 1,
HPRT= Hypoxanthine Guanine Phosphoribosyl Transferase loading control. B.
Diminished response to oxidant stress was indicated by reduced expression of
DDIT3 (DNA-damage-inducible transcript 3) in immature Ets1ilVil thymocytes.
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1

1

isoform-specific differences. One strategy to address this problem is the
knock-down of

Ets1~VII

expression with siRNA (van de Wetering, Oving et al.

2003). This could be achieved with siRNAs directed to Ets1 in

Ets1~VII

homozygotes. Additionally siRNAs specific for exon VII could be used in wildtype cells, and this would offer the added benefit of testing to see if
autoregulation of Ets1 is due to feedback mechanisms controlling Ets1 or loss
of intronic regulatory sequences in the construction of Ets1 ~ VII mice. An
alternate strategy, assuming the successful generation of the full-length Ets1
only (Ets1 ~ VII-less) gene targeted mice, would be the generation of a
compound heterozygote that is Ets1L\Vll/p51. This would potentially create an in
vivo system with the expected upregulation of full-length Ets1 expression and

blunted expression of

Ets1~VII,

which would allow for clarification of the roles

of Ets1 isoform expression levels in the observed phenotypes. Furthermore,
because if the complexity of the in vivo system, it is unclear if the gene that
are misregulated in Ets1 mutant mice are direct or indirect targets of Ets1.
One method to distinguish between direct and indirect regulation is chromatin
immunoprecipitation (ChiP) (Kuo and Allis 1999). ChiP analysis could reveal
the presence or absence of Ets1 on the promoters of Cdkn1 b, Cdkn2a,
Runx1, CD44, and Ets1. While progress has been made in determining the
mechanism of increased cell proliferation in lymphoid organs, the mechanistic
characterization of the apoptotic pathway is lagging. Expression of apoptotic
regulatory genes such as Scl2 and Sax should be evaluated to determine the
mode of apoptosis. To determine if these effects are intrinsic to lymphocytes,
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or depend upon microenvironmental cues, Ets1f1oxedL\VII mice could be bred
with mice expressing Cre recombinase under a lymphocyte specific promoter.
Additionally apoptotic and proliferative cells may be immunophenotyped by
flow cytometry with cell-type and proliferation/apoptotic markers, to determine
the exact lineages affected.

In a broader sense, our data support a model whereby Ets1L\VII may act as a
downstream amplifier of pre-TCR signals. This is plausible mechanistically,
given that the pre-TCR proliferative signal is transduced by Ras/Erk1/2 which
may impinge on Ets1. ERK1/2 phosphorylation of THR3S residue common to
both isoforms of Ets1 has been demonstrated to augment Ets1 transcriptional
activity (Seidel and Graves 2002). Given that all thymocyte subpopulations
are expanded in Ets1 L\VII mice it is likely that the phenotype arises in or
before the earliest, CD4-CDS-, stage. Of note, CD4-CDS- cells have a lower
threshold for ligand independent pre-TCR signaling, based in part upon
increased Ca 2+ capacitive entry (Haks, Belkowski et al. 2003; Puthier, Joly et
al. 2004), indicating that these cells may be more sensitive to transgenic Ets1
expression since Ca 2+ flux mediated signaling normally represses full-length,
but not Ets1L\VII transcriptional activity. In this light Ets1L\VII is not only
expressed at higher levels than normal, but it also represents a more active
transcriptional regulator based upon THR3S, and has lost responsive to the
inhibitory Ca2 + signal. TCR signaling regulates survival, proliferation,
differentiation and allelic exclusion in thymocytes, with ERK1/2 transducing
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signals for proliferation and differentiation (Cantrell 2002). Given the
plausibility of TCR signaling defects underlying the proliferative and apoptotic
defects in these mice activation studies should be preformed to directly
assess the function of the TCR and TCR signaling. This may be done by in

vitro crosslinking of the TCR with a-CD3, and measurement of proliferative
and apoptotic response.
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Chapter 5: Materials and Methods
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5.1 Mice.
Mice were generated as described in Section 2: Generation of an Allelic Series of
Ets1 Mutant Mice. All mice were housed under specific pathogen-free conditions,
and experiments were performed in accordance with the institutional guidelines
for animal care at the Medical University of South Carolina under approved
protocols.

5 . 2 Southern Blot Analysis
Genomic DNA was isolated from ES cells or mouse Tails using 50S lysis buffer
(100mM NaCI, 50mM Tris pH=8.8, 100mM EDTA, 1% 80S) and proteinase K.
200uL of saturated NaCI (-6M) was added and tubes were shaken vigorously for
200 repetitions. After placing on ice for 10 minutes, samples were centrifuged at
10,000 rpm. The supernatant was removed and precipitated with 95 % ethanol.
10,...g of DNA was digested with BamHI and electrophoresed on a 1% TBE
agarose gel. The gel was depurinated in 0.20 M HCI for 15 minutes. Afterwards,
the gel was denaturated in 0.5M NaOH, 1.5M NaCI for 2x 20 minutes followed by
neutralization in 3M NaCI, O.5M Tris pH=7.0, for 45 minutes. The DNA was then
blotted onto nitrocellulose membrane (Duralon, Stratagene, La JoUa, Calif) and
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hybridized using random-primed syntheses and Quick Hybe (Stratagene, La
Jolla, Calif).

5.3 Real-Time peR.
Total RNA was isolated from flow sorted thymocyte subpopulations using RNA
Stat 60 reagent (Tel-Test #Cs-111 ) according to manufacturer's protocol.
Isolated RNA was DNasel treated to remove genomic DNA. The RNA was
reverse transcribed using Advantage RT for PCR Kit (Clontech # 639505) with
oligo(dT) primers. qPCR reactions were done in duplicates using Platinum
SYSR Green qPCR SuperMix-UDG (Invitrogen #11733-038) ASI Prism 5700
real-time PCR machine (Applera). Relative transcript expression was
determined by AACT method: relative expression=2-(ACTsamPIe-ACTf3Actin), where
CT=threshold cycle. Primers were designed to span intron sequences when
possible, and were tested by non-quantitative RT-PCR to verify that only one
amplicon was produced. The_Ets1full-length specific primer set includes one primer
that binds to exon VII sequence. The Ets1 AVII specific primer set includes one
primer that spans the exon VI-VIII junction.

5.4 Semi..Quantitative RT -peR.
1Jlg of total RNA was reverse transcribed using Advantage RT for PCR Kit
(Clontech # 639505) with oligo(dT) primers. 0.5 f.ll from this reaction was
subjected to peR using primers indicated. The reaction mixture contained 1.5mM
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Expression Primers

~

........
........

,6-Actin For
,6-Actin Rev
Cdkn1b For
Cdkn1b Rev
Cdkn2a FOR
Cdkn2a REV
Cdh5 For
Cdh5 Rev
Csf2 For
Csf2 Rev
Ets1 AV il For
Ets_1 11VII Rev
Ets-1 full-length For
Ets1 full-length Rev
Runx1 For
Runx1 Rev

CCGGGACCTGACAGACTACC
TGCCACAGGATTCCATACCC
CAG GCAAACTCTGAGGAC CG
CCTTTTGTTTTGCGAAGAAGAATC
CAGGTGATGATGATGGGCAAC
CAGCGTGTCCAGGAAGCCT
TCCCCGTCTTTACTCAATCCA
TCCGGTTCTGAGGCTCATCT
CGGAAACGGACTGTGAAACA
ATTACGCAGGCACAAAAGCA
AGAGCCAGTCGTGGAAGTGG
CGCACGGCTCAGTTTCTCAT
TAGTTGTGACCGCCTCACCC
TCGGCCCACTTCCTGTGTAG
GAAATGCCAGGCAGATCCAG
GGAGCCGTTGAGAGTCGACT

NM_007393
NM_009875
NM_001040654
NM_009868
NM_009969
NM_001038642
NM- 011 808
NM_009821

626·,645
900-881
870-889
1004-981
205-225
339-321
811 -831
921-902
606-625
775-756
1060-1079
1257-1238
1119-1138
1345-1326
2103-2122
2274-2255

20
20
20
24
21
19
21
20
20
20
20
20
20
20
20
20

65.8

65

66.8
67.1
65.6
67.6
67.9
65.4
66.2
66.0
65.4
66.7
67.6
67.3
67.4
66.8
65.8

55
60
38
52
63
48
55
50
45
60
55
60
60
55
60

21

72.3

62

22

68.5

59

227

\Nild Type

23

73.3

55

454

Mutant

21

72.3

62

23

65.9

52

238

r,,1ut ant

23

76.2

65

446

Wild Typ-e

274
134
134
110
169
197
226
171

Genotyping Primers
Ets1AVII

p1-INT6F

CAG GCCAGCATCCTTTCC CCT

p2-INT5R

TAG GAAGAG GGCAGG GAAGAGG

p3-INT7ClaR

GCCCACCAGGTCACAGGACTCAG

AC139108
Strain: C578UGJ

8279682776
8263082651
823518 2 376~

Common

Ets1SA

p1-INT6F

CAGGCCAGCATCCTTTCCCCT

p2-MutCHKR

CAAGCATCGTAAGCCTCTACAGC

AC139108
Strain. C578UGJ

p3-MEf7R

TGTGTAGCCAGCCAGGGCAGCAG

"C5781.i6 and 129 strains are polymorphic at this binding site
Red lettering denotes exon VINIII junction of Ets1

8279682776
8258182559
8013780157

Common

Mg2+ ,0.2 mM dNTPs, 1x Amplitaq Gold buffer II, 0.88pmollJ.d primers, and 0.02

U/J..l1 Amplitaq gold. Basic PCR cycling parameters were: 95°C for 12 minutes
followed by the indicated number of cycles of 95°C for 1 minute, 55°C for 1
minute, 72°C for 1 minute. A polishing step of 72°C for 10 minutes was included
at the end of the cycling. PCR products were run on a 30/0 agarose gel containing
Ethidium Bromide in T AE buffer. Products were visualized by UV light.

5.5 Western Blot Analysis.
Spleens and thymuses were isolated and filtered through 40uM mesh cell
strainer (BD #352340). Strained thymocytes and splenocytes were resuspended
in modified radioimmunoprecipitation assay (RIPA) buffer with Protease Inhibitors
(Roche #1836153), and quantitated by BCA method (Peirce #23225). 70ug of
total spleen protein or 25-40ug of total thymus protein was electrophoresed on
12.5% SDS polyacrylamide gel. The following antibodies were used:

~-Actin,

Ets1 c-20 (Santa Cruz sc-350), Runx1 (Calbiochem PC284l), Cdkn1 b (Santa
Cruz sc-528), Cdkn2a (Santa Cruz sc-1207), a-mouse-HRP (Caltag #M30007) arabbit-HRP (Caltag #l42007). Membranes were developed using WestPico ECl
kit (Pierce #34079).

5.6 Flow Cytometry and Cell Sorting
Single-cell suspensions were obtained by mechanical disruption of thymus or
spleen, and strained through 40uM cell strainer (BD#352340). Cells (2 x 105 )
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were blocked with anti-Fc receptor (BD#553141 ) and stained with combinations
of antibodies listed. The antibodies used in these experiments included: CD94
(Pharmingen#550773), CD4 (Pharmingen#557307), CD8 (Pharmingen#553032,
553034), CD19 (Pharmingen#557398), CD44 (Pharmingen#553134), Gr-1
(Pharmingen#553128), Mac1(Pharmingen#557395). For Annexin V staining,
cells were stained using (BD#556547) according to manufacturer's instructions.
Two- or three -color flow cytometric analyses were performed on a FACScalibur
4

(Becton-Dickinson). Each dot plot or histogram represents analysis of 10 events
using Win MOl software version 2.8.

5.7 BrDU Labeling Histology and IHC
For detection of BrdU incorporation by splenocytes and thymocytes in vivo, 1.5
mg BrdU (Sigma, # B5002) in 150uL PBS in sterile PBS was injected
intraperitoneally 4 hours before organ isolation. Spleen and Thymus were fixed in
Amsterdam's fixative, paraffin embedded, and serially sectioned in 7um sections.
For histological evaluation the sections were stained with hematoxylin and eosin
(H&E). For IHC detection of BrdU incorporation into the DNA of dividing cells,
sections were deparaffinized and hydrated. Endogenous peroxidase was
inhibited by incubation with freshly prepared 3% H202 with 0.1 % sodium azide.
DNA was denatured by acid treatment, and nonspecific binding was blocked with
2% BSA in PBS. Sections were incubated with monoclonal a-BrdU antibody (BD
Pharmingen #347580) 1:150 dilution, overnight at 4°C followed by a-mouse HRP
(Dako). After incubation with primary antibody, tissue sections were sequentially

179

incubated with goat anti-mouse HRP (Dako) at dilution of 1:100. Staining was
developed with diaminobenzidine (DAB; Vector #SK41 00) substrate and sections
were counterstained with hematoxylin.

5.8 Statistics
Data are reported as mean±SEM. Differences in means were analyzed by
unpaired t-test or ANOVA as appropriate depending upon number of groups in
analysis. Unpaired t-tests were used for post hoc testing.
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